aldosterone has been researched along with eplerenone in 263 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.38) | 18.2507 |
| 2000's | 129 (49.05) | 29.6817 |
| 2010's | 116 (44.11) | 24.3611 |
| 2020's | 17 (6.46) | 2.80 |
| Authors | Studies |
|---|---|
| Álvarez de la Rosa, D; Gerona-Navarro, G; González-Muñiz, R; Martín-Martínez, M; Pérez-Gordillo, FL; Rodríguez, Y; Zhou, MM | 1 |
| Borkowski, J; Gentsch, C; Mondadori, C | 1 |
| Chadow, HL; Hameedi, A | 1 |
| Adler, GK; Kifor, I; Ochoa-Maya, MR; Rennke, HG; Rocha, R; Stier, CT; Williams, GH | 1 |
| Epstein, M | 3 |
| Bobik, A; Funder, J; Kanellakis, P; Ramsey, D; Ward, MR | 1 |
| Pfeffer, MA | 1 |
| Bittman, R; Burns, D; Hurley, S; Kleiman, J; Lopez-Sendon, J; Martinez, F; Neaton, J; Pitt, B; Remme, W; Roniker, B; Williams, G; Zannad, F | 1 |
| Funder, JW | 6 |
| McMahon, EG | 2 |
| Adler, GK; Martinez, DV; Matsumura, M; Ochoa-Maya, M; Oestreicher, E; Rocha, R; Roubsanthisuk, W; Williams, GH | 1 |
| Cook, CS; Zhang, L | 1 |
| Funder, JW; Mardini, M; Mihailidou, AS; Raison, M | 1 |
| Funder, JW; Rocha, R | 1 |
| Blomme, EA; Delyani, JA; Frierdich, GE; Kekec, BK; McMahon, EG; Nachowiak, DA; Rocha, R; Rudolph, AE | 1 |
| Weber, MA | 1 |
| Krum, H; Liew, D | 3 |
| Delyani, J; Martin-Berger, CL; McMahon, E; Rocha, R; Scherrer, R; Yang, P | 1 |
| Benetos, A; Delcayre, C; Labat, C; Lacolley, P; Pujol, A; Safar, M | 1 |
| Brown, R; Kirkpatrick, P; Quirk, J | 1 |
| Alzamora, R; Gonzalez, M; Marusic, ET; Michea, L | 1 |
| Badoual, T; Cachin, JC; Castaigne, A; Hittinger, L; Le Corvoisier, P; Lopes, ME; Merlet, P; Su, JB; Tabet, JY | 1 |
| Jessup, M | 1 |
| Blasi, ER; Blomme, EA; McMahon, EG; Polly, ML; Rocha, R; Rudolph, AE | 1 |
| Flack, JM; Garthwaite, S; Kleiman, JH; Krause, SL; Oparil, S; Pratt, JH; Roniker, B; Saunders, E; Workman, D; Yang, Y | 1 |
| Ben-Yehuda, O | 1 |
| Pitt, B; Rajagopalan, S | 1 |
| Brown, NJ | 1 |
| Conti, CR | 1 |
| Aviram, M; Coleman, R; Hamoud, S; Hayek, T; Kaplan, M; Keidar, S; Pavlotzky, E | 2 |
| Blomme, EA; Bond, BR; Funder, JW; Goellner, JJ; McMahon, EG; Qin, W; Rocha, R; Rudolph, AE | 1 |
| Carr, AA; Jordan, R; Krause, S; Oigman, W; Roniker, B; White, WB | 1 |
| Lakkis, J; Lu, WX; Weir, MR | 1 |
| Pitt, B | 2 |
| Kolloch, R; Offers, E | 1 |
| Abe, Y; Kagami, S; Kimura, S; Kiyomoto, H; Kohno, M; Kondo, S; Miyata, K; Nagai, Y; Nishiyama, A; Shokoji, T; Yao, L; Yoshizumi, M | 1 |
| MacDonald, TM; Struthers, AD | 1 |
| Christ, M; Grimm, W; Maisch, B | 1 |
| Davies, JI; Dawson, A; Struthers, AD | 1 |
| Black, HR | 1 |
| Endemann, DH; Iglarz, M; Savoia, C; Schiffrin, EL; Touyz, RM | 1 |
| Akino, M; Denhardt, D; Jia, N; Kitabatake, A; Kon, S; Liu, L; Matsui, Y; Morimoto, J; Okamoto, H; Onozuka, H; Rittling, SR; Uede, T | 1 |
| Coghlan, JP; Tait, JF; Tait, SA | 1 |
| Garthwaite, SM; McMahon, EG | 1 |
| Apriletti, JW; Baxter, JD; Funder, JW; Webb, P | 1 |
| McMahon, EG; Rocha, R; Rudolph, AE | 1 |
| Khan, NU; Movahed, A | 1 |
| Gumieniak, O; Williams, GH | 1 |
| Struthers, AD | 1 |
| Weinberger, MH | 1 |
| Delpiano, AM; Hitschfeld, C; Lavandero, S; Lobos, L; Marusic, ET; Michea, L | 1 |
| Fuller, PJ; Rogerson, FM; Smith, BJ; Yao, Y | 1 |
| Dietz, JD; Du, S; Hu, X; Hultman, ML; Krasnoperova, NV; Lala, DS; Li, S; Welsch, DJ; Xia, C | 1 |
| Yamamoto, T; Yano, M | 1 |
| Heinzl, S | 1 |
| Takeda, Y | 2 |
| Balfagón, G; Cachofeiro, V; Cediel, E; de las Heras, N; Lahera, V; Miana, M; Sanz-Rosa, D | 1 |
| Fujita, Y; Ishizawa, K; Ito, H; Izawa, Y; Kanematsu, Y; Miki, C; Miyata, K; Nishiyama, A; Tamaki, T; Tsuchiya, K; Yoshizumi, M | 1 |
| Kitamura, K; Tomita, K | 1 |
| Hu, X; Lala, DS; Li, S; McMahon, EG; Rudolph, AE | 1 |
| Herman, ZS; Krysiak, R; Okopień, B | 1 |
| Abassi, Z; Gamliel-Lazarovich, A; Hamoud, S; Hayek, T; Kaplan, M; Karry, R; Keidar, S; Pavlotzky, E | 1 |
| Strawn, WB | 1 |
| Kusano, E; Miyata, Y; Muto, S | 1 |
| Abe, K; Nakao, K; Nakayama, M; Ogawa, H; Saito, Y; Sakamoto, T; Shono, M; Suzuki, S; Yamamuro, M; Yasue, H; Yoshimura, M | 1 |
| Abe, Y; Nishiyama, A | 1 |
| Higaki, J; Horiuchi, M; Iwai, M; Mogi, M; Oshita, A; Suzuki, J; Yoshii, T | 1 |
| Chai, W; Danser, AH; de Vries, R; Garrelds, IM | 1 |
| Milan, A; Mulatero, P; Veglio, F; Verhovez, A; Williams, TA | 1 |
| Ichihara, S; Izawa, H; Kato, T; Kimata, H; Murohara, T; Nagata, K; Noda, A; Obata, K; Xu, J; Yokota, M | 1 |
| Milan, A; Mulatero, P; Veglio, F; Williams, TA | 1 |
| Bayorh, MA; Eatman, D; Mann, G; Walton, M | 1 |
| Asano, Y; Fujita, M; Hirata, A; Hori, M; Kitakaze, M; Minamino, T; Okada, K; Sanada, S; Shintani, Y; Takashima, S; Tomoike, H; Tsukamoto, O; Yamasaki, S; Yulin, L | 1 |
| Fan, CY; Kawai, Y; Miyamori, I | 1 |
| Matsubara, H; Tatsumi, T | 1 |
| Chen, YF; Feng, JA; Franco, V; Hasan, E; Li, P; Oparil, S; Perry, GJ; Wang, D | 1 |
| Armstrong, S; Ding, Q; Feldman, RD; Gros, R; O'Neil, C; Pickering, JG | 1 |
| Athyros, VG; Florentin, M; Kakafika, A; Karagiannis, A; Tziomalos, K | 1 |
| Hori, M; Mano, T; Masuyama, T; Miwa, T; Nishio, M; Nonaka, Y; Ohta, M; Ohtani, T; Okamoto, M; Sakata, Y; Takeda, Y; Yamamoto, K; Yoshida, J | 1 |
| Ando, K; Fujita, T; Gotoda, T; Nagase, M; Nagase, T; Shibata, S; Yoshida, S | 1 |
| Abe, Y; Izumi, T; Mochizuki, S; Taniguchi, I; Urabe, A | 1 |
| Fujita, T; Kawachi, H; Nagase, M; Shibata, S; Yoshida, S | 1 |
| Hirata, Y; Hirono, Y; Kobayashi, N; Sakurada, M; Shichiri, M; Sugiyama, T; Suzuki, N; Takai, S; Yoshimoto, T | 1 |
| Inagaki, K; Makino, H; Miyoshi, T; Mukai, T; Ogura, T; Otani, H; Otsuka, F; Suzuki, J; Takeda, M | 1 |
| Altenhenne, C; Büchner, NJ; Dekomien, G; Epplen, JT; Hofebauer, S; Maser-Gluth, C; Rump, LC; Sellin, L; Vonend, O; Weiner, SM | 1 |
| Aragoncillo, P; Cachofeiro, V; de las Heras, N; Egido, J; Lahera, V; Mezzano, S; Miana, M; Ruiz-Ortega, M; Rupérez, M; Sanz-Rosa, D | 1 |
| Hausberg, M; Hillebrand, U; Oberleithner, H; Riethmüller, C; Schillers, H; Stock, C; Wilhelmi, M | 1 |
| Fujita, T; Goto, A; Kobayashi, N; Matsuoka, H; Onozato, ML; Tojo, A | 1 |
| Hiroe, M; Imanaka-Yoshida, K; Inada, H; Nishioka, T; Onishi, K; Suzuki, M; Takakura, N; Yoshida, T | 1 |
| Yamamoto, T | 1 |
| Francis, GS; Kalidindi, SR; Tang, WH | 1 |
| Kitajima, H; Kusaka, T; Nishiyama, A | 1 |
| Hirata, Y; Nagata, D | 1 |
| Chabielska, E; Gromotowicz, A; Skrzypkowski, P; Stankiewicz, A; Szemraj, J; Wojewódzka-Zelezniakowicz, M | 1 |
| Brandes, RP | 1 |
| Fujita, T; Gotoda, T; Matsui, H; Nagase, M; Shibata, S | 1 |
| Takata, H; Takeda, Y; Usukura, M; Yamagishi, M; Yoneda, T; Zhu, A | 1 |
| Hirata, Y; Hirono, Y; Iwashima, F; Minami, I; Sakurada, M; Yoshimoto, T | 1 |
| Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Tsujioka, H; Yoshida, K | 1 |
| Bauersachs, J; Ertl, G; Fraccarollo, D; Galuppo, P; Kneitz, S; Schraut, S; van Rooijen, N | 1 |
| Kushibiki, M; Okumura, K; Osanai, T; Tomita, H; Yamada, M | 1 |
| Chander, PN; Chaudhary, AN; Ding, G; Gupta, A; Liang, W; Mathew, JT; Patni, H; Singhal, PC | 1 |
| De Mello, WC; Gerena, Y | 1 |
| Ando, K; Fujita, M; Fujita, T; Kawarazaki, H; Matsui, H; Nagae, A; Nagase, M; Shimosawa, T | 1 |
| Abe, K; Nakao, K; Nakayama, M; Ogawa, H; Saito, Y; Sugiyama, S; Sumida, H; Yamamuro, M; Yasue, H; Yoshimura, M | 1 |
| Leopold, JA; Maron, BA | 1 |
| Diah, S; Gang, L; Hamid, MR; Hitomi, H; Kimura, S; Nagai, Y; Nishiyama, A; Tamiya, T; Zhang, GX; Zhang, W | 1 |
| Hlavacova, N; Jezova, D | 1 |
| Kiyomoto, H; Mostofa, M; Nishiyama, A; Rafiq, K | 1 |
| Gabor, A; Leenen, FH | 1 |
| De Silva, DS; Garcia, AG; Hutchinson, C; Ip, PC; Ito, M; Lancel, S; Pimentel, DR; Sam, F; Wilson, RM | 1 |
| Becker, GJ; Chrysostomou, A; Hewitson, TD | 1 |
| Danser, AH; Imholz, BP; Jansen, PM; van den Meiracker, AH | 1 |
| Homma, I; Iigaya, K; Kobayashi, Y; Minoura, Y; Onimaru, H | 1 |
| Kinouchi, T; Kitazato, KT; Nagahiro, S; Satomi, J; Shimada, K; Tada, Y; Tamura, T; Yagi, K | 1 |
| Miller, AB; Shafiq, MM | 1 |
| Stowasser, M | 1 |
| Bakos, J; Hlavacova, N; Jezova, D | 1 |
| Fukuda, S; Sato, A | 2 |
| Goto, K; Iida, M; Kagiyama, S; Matsumura, K; Otsubo, T | 1 |
| Bokuda, K; Ichihara, A; Itoh, H; Kinouchi, K; Kurauchi-Mito, A; Mizuguchi, Y; Narita, T; Sakoda, M; Seki, Y | 1 |
| Hirayama, K; Kitayama, T; Kosaka, H; Kusaka, H; Matsubara, M; Sasaki, K; Yoda, N | 1 |
| Adamová, Z; Adler, GK; Khalil, RA; Kumar, A; Pojoga, LH; Romero, JR; Stennett, AK; Williams, GH | 1 |
| Alexopoulos, D; Apostolakis, E; Gkizas, SI; Koletsis, E; Mavrilas, D; Pagoulatou, E; Papachristou, DJ; Papadaki, H; Papalois, A | 1 |
| Fujita, T; Nagase, M | 1 |
| Bunda, S; Hinek, A; Mitts, TF; Wang, Y | 1 |
| Adler, GK; Garg, R; Tirosh, A | 1 |
| Chen, C; Ding, G; Hu, F; Liang, W; Ren, Z; Shi, J; Singhal, PC; van Goor, H | 1 |
| Stier, CT | 1 |
| Simoni, J; Wesson, DE | 1 |
| Bauersachs, J; Dietrich, B; Ertl, G; Fleissner, F; Hahner, S; Jazbutyte, V; Schmitter, K; Thum, T; Widder, JD; Wiebking, V | 1 |
| Chabielska, E; Gromotowicz, A; Mantur, M; Osmólska, U; Szemraj, J; Szoka, P; Zakrzeska, A | 1 |
| Guglin, M; Kristof-Kuteyeva, O; Novotorova, I; Pratap, P | 1 |
| Hitomi, H; Nakano, D; Nishiyama, A; Rafiq, K | 1 |
| Fan, YY; Felder, RA; Fujisawa, Y; Hitomi, H; Kitada, K; Kohno, M; Nakano, D; Nishiyama, A; Noma, T; Ohsaki, H; Rafiq, K; Sherajee, SJ; Yatabe, J; Yatabe, M | 1 |
| Adiyiah, J; Bayorh, MA; Eatman, D; Lyn, D; Rollins-Hairston, A | 1 |
| März, W; Pilz, S; Tomaschitz, A | 1 |
| Horiuchi, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Ohshima, K; Sakata, A; Tsukuda, K | 1 |
| Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yasuda, O | 1 |
| Ando, K; Fujita, M; Fujita, T; Kawarasaki, C; Kawarazaki, H; Matsui, H; Muraoka, K; Nagae, A | 1 |
| Agostoni, P; Boccanelli, A | 1 |
| Godfrey, V; Lyles, GA; Martin, AL; Struthers, AD | 1 |
| Chasiotis, H; Kelly, SP | 1 |
| Denhardt, DT; Desilva, VR; Enomoto, D; Higaki, J; Irita, J; Jotoku, M; Kurata, M; Matsui, Y; Miyoshi, K; Nagao, T; Okura, T; Rittiling, SR; Uede, T | 1 |
| Briones, AM; Callera, GE; He, Y; Montezano, AC; Nguyen Dinh Cat, A; Touyz, RM; Yogi, A | 1 |
| Chorazyczewski, J; Davis, M; Ding, Q; Feldman, RD; Gros, R; Liu, B; Pickering, JG; Shaikh, R | 1 |
| Krysiak, R; Okopien, B | 1 |
| Connell, JM; Dargie, HJ; Fraser, R; McMurray, JJ; Steedman, T; Tsorlalis, IK; Weir, RA | 1 |
| Crook, MF; Flattery, AM; Forrest, G; Forrest, MJ; Pan, Y; Roy, S; Ruben, Z; Sharif-Rodriguez, W; Szeto, D; Urosevic-Price, O; Wang, L; Zhao, H; Zhou, X; Zhu, Y | 1 |
| Sica, DA | 2 |
| Banker, ME; Boustany-Kari, CM; Eudy, RJ; King-Ahmad, A; Loria, P; Near, K; Piotrowski, DW; Sahasrabudhe, V; Sweeney, K; Tugnait, M | 1 |
| Hamada, K; Horino, T; Inoue, K; Kagawa, T; Ogata, K; Shimamura, Y; Takao, T; Taniguchi, Y; Terada, Y; Ueda, S | 1 |
| Richards, AM | 1 |
| Funder, J | 1 |
| Deguchi, K; Hitomi, H; Kitada, K; Kobori, H; Lei, B; Masaki, T; Minamino, T; Mori, H; Nakano, D; Nishiyama, A | 1 |
| Fujita, Y; Hara, T; Hitomi, H; Kohno, M; Masaki, T; Mori, H; Nakano, D; Nishiyama, A; Rafiq, K; Sherajee, SJ | 1 |
| Arakawa, K; Fujii, M; Inaba, S; Inoki, I; Konoshita, T; Miyamori, I; Morikawa, N; Saga, M; Yoshioka, K | 1 |
| Hirooka, Y; Hoka, S; Ito, K; Matsukawa, R; Nakagaki, T; Nakano, M; Nishihara, M; Sunagawa, K | 1 |
| James, RW; Mach, F; Maturana, AD; Pagano, S; Python, M; Rossier, MF; Roux-Lombard, P; Vuilleumier, N | 1 |
| Bertello, C; Fallo, F; Giraudo, G; Monticone, S; Mulatero, P; Urbanet, R; Veglio, F; Vettor, R; Williams, TA | 1 |
| Ayuzawa, N; Fujita, T; Ishizawa, K; Kawarazaki, W; Nagase, M; Takeuchi, M; Ueda, K; Yoshida, S | 1 |
| Albert, NM; Butler, J; Carson, PE; Collins, SP; Colvin-Adams, M; Ezekowitz, JA; Fang, JC; Givertz, MM; Hernandez, AF; Hershberger, RE; Katz, SD; Rogers, JG; Spertus, JA; Starling, RC; Stevenson, WG; Stough, WG; Sweitzer, NK; Tang, WH; Teerlink, JR; Walsh, MN; Westlake Canary, CA | 1 |
| Azibani, F; Benard, L; Carrier, L; Chatziantoniou, C; Delcayre, C; Fazal, L; Launay, JM; Merval, R; Polidano, E; Samuel, JL; Schlossarek, S; Tournoux, F | 1 |
| Adiyiah, J; Bayorh, M; Eatman, D; Lyn, D; Rollins-Hairston, A | 1 |
| Filippatos, G; Gheorghiade, M; Kim, SY; Kober, L; Kolkhof, P; Krum, H; Nowack, C; Pitt, B; Ponikowski, P; Zannad, F | 1 |
| Behar-Cohen, F; Bousquet, E; Célérier, I; Curan, A; Farman, N; Jaisser, F; Jeanny, JC; Jonet, L; Offret, O; Savoldelli, M; Zhao, M | 1 |
| Krum, H; Watanabe, M | 1 |
| Beuschlein, F; Potthoff, SA; Vonend, O | 1 |
| Coleman, R; Gamliel-Lazarovich, A; Gantman, A; Keidar, S; Raz-Pasteur, A | 1 |
| Alvarez de la Rosa, D; Clément, K; Delcayre, C; Farman, N; Gravez, B; Jaisser, F; Launay, JM; Messaoudi, S; Ouvrard-Pascaud, A; Pelloux, V; Samuel, J; Sierra-Ramos, C; Tarjus, A | 1 |
| Kumagai, H; Nishida, Y; Oda, T; Onimaru, H; Oshima, N; Takechi, H; Uchida, T; Watanabe, A; Yamamoto, K | 1 |
| Chen, D; Han, H; Huang, Y; Li, W; Li, Z; Ma, C; Peng, Y; Wei, J; Wu, W; Zhan, F | 1 |
| Anegawa, T; Hirooka, Y; Imaizumi, T; Kage, M; Kai, H; Kajimoto, H; Koga, M; Kudo, H; Mifune, H; Miyamoto, T; Takayama, N; Yasuoka, S | 1 |
| Coleman, R; Gamliel-Lazarovich, A; Keidar, S; Raz-Pasteur, A | 1 |
| Bułdak, Ł; Liber, J; Liber, S; Machnik, G; Okopień, B; Łabuzek, K | 1 |
| Berger, S; Lohmann, C; Lüscher, TF; Matter, CM; Miranda, MX; Nussberger, J; Ruschitzka, F; Schäfer, N; van Tits, LJ; Vergopoulos, A; Verrey, F; Winnik, S | 1 |
| Araki, N; Ishigami, T; Kakizoe, Y; Kitamura, K; Maeda, E; Minegishi, S; Tamura, K; Umemura, M; Umemura, S; Ushio-Yamana, H | 1 |
| Cassis, LA; Daugherty, A; Gong, MC; Guo, Z; Liu, S; Pearson, KJ; Xie, Z | 1 |
| Dostal, DE; Jewell, C; Song, J; Watson, LE | 1 |
| Antunes, TT; Callera, GE; Miquel, P; Montezano, AC; O'Connor, S; Perraud, AL; Schmitz, C; Shrier, A; Touyz, RM; Valinsky, W; Yogi, A | 1 |
| Ahmad, M; Huang, BS; Leenen, FH; White, RA | 1 |
| Weiner, ID | 1 |
| Casaldàliga, J; Dos, L; Estruch, M; Ferreira-González, I; García-Dorado, D; Marsal, JR; Mas, A; Ordóñez-Llanos, J; Pijuan, A; Pons-Lladó, G; Pujadas, S; Serra, R; Subirana, M | 1 |
| Cheng, SB; Dong, J; Filardo, EJ; Hixon, M; LaRocca, J; Pang, Y; Thomas, P | 1 |
| Bobrzyk, M; Bułdak, Ł; Krupej-Kędzierska, J; Liber, S; Machnik, G; Okopień, B; Łabuzek, K | 1 |
| Asayama, K; Elnagar, N; Hosaka, M; Imai, Y; Ishikura, K; Mano, N; Obara, T; Ohkubo, T; Satoh, M | 1 |
| Anzawa, R; Date, T; Fujisaki, M; Hongo, K; Ito, K; Kashiwagi, Y; Katoh, D; Kayama, Y; Nagoshi, T; Yoshimura, M; Yoshino, T | 1 |
| Isaka, Y; Kawada, N; Kitamura, H; Moriyama, T; Rakugi, H | 1 |
| Carretero, OA; D'Ambrosio, MA; Garvin, JL; Kutskill, K; Leung, P; Peterson, EL; Ren, Y; Wang, H | 1 |
| Leenen, FH; Rafatian, N; Westcott, KV; White, RA | 1 |
| Amâncio, Gde C; de Assis, LV; Faria, Gde O; Hermidorff, MM; Isoldi, MC | 1 |
| Chen, YP; Li, M; Rui, HL; Sun, QL | 1 |
| Amann, K; Brand, S; Mandel, P; Schupp, N; Zimnol, A | 1 |
| Chudek, J; Maruniak-Chudek, I; Olszanecka-Glinianowicz, M; Sikora, J; Wyskida, K; Wyskida, M | 1 |
| Aoki, K; Arai, K; Homma, T; Ishikawa, H; Mizuno, M; Morikawa, Y; Sada, T; Tsuruoka, H; Ubukata, N | 1 |
| Deinum, J; Lenders, JW; Riksen, NP | 1 |
| Gaudio, C; Greco, C; Lainscak, M; Pelliccia, F; Rosano, G; Schiariti, M; Speziale, G; Vitale, C | 1 |
| Ahmad, M; Chen, A; Huang, BS; Leenen, FH; Wang, HW; White, RA | 1 |
| Korantzopoulos, P; Letsas, KP; Li, G; Liu, T; Shao, Q; Zhang, Z | 1 |
| Anzai, K; Kawate, H; Matsuda, Y; Matsuzaki, C; Nomura, M; Ohnaka, K; Sakamoto, R; Shibue, K; Takayanagi, R | 1 |
| Bomback, AS | 1 |
| Bian, Z; Chen, P; Gu, H; Guo, L; Hu, C; Pan, Y; Zhang, Y; Zhu, S | 1 |
| Yang, J; Young, MJ | 1 |
| Bleich, M; de Bruijn, PI; Jensen, IS; Larsen, CK; Leipziger, J; Praetorius, HA; Sorensen, MV | 1 |
| Belyavskiy, E; Brandenburg, VM; Brussee, H; Catena, C; Fahrleitner-Pammer, A; Gaksch, M; Grübler, MR; März, W; Meinitzer, A; Perl, S; Pieske, B; Pilz, S; Scharnagl, H; Sechi, LA; Tomaschitz, A; Van Ballegooijen, AJ; Verheyen, N; Wetzel, J | 1 |
| Kaplan, NM | 1 |
| Jolly, A; Miquel, P; Shrier, A; Touyz, RM; Valinsky, WC | 1 |
| An, Y; Guo, A; Li, Y; Liu, T; Wang, M; Wang, Y; Zhang, G; Zhang, Y; Zhou, K | 1 |
| Bornstein, SR; Brown, NF; Brunssen, C; Deussen, A; Eisenhofer, G; Engelmann, F; Hofmann, A; Huber, J; Jannasch, A; Martin, M; Mittag, J; Morawietz, H; Peitzsch, M; Streicher, R; Weldon, SM | 1 |
| Asbach, E; Bidlingmaier, M; Fourkiotis, V; Gerum, S; Lichtenauer, UD; Manolopoulou, J; Quinkler, M; Reincke, M | 1 |
| Adler, GK; Baudrand, R; Ferri, C; Garza, AE; Gupta, N; Hopkins, PN; Jeunemaitre, X; Leopold, JA; Loscalzo, J; Pojoga, LH; Romero, JR; Vaidya, A; Williams, GH; Williams, J | 1 |
| Dhople, VM; Felix, SB; Gross, S; Hammer, E; Könemann, S; Samal, R; Völker, U; Wenzel, K | 1 |
| Channar, PA; El-Seedi, H; Faisal, M; Larik, FA; Mehfooz, H; Saeed, A; Shahzad, D | 1 |
| Collier, TJ; Girerd, N; Lamiral, Z; Machu, JL; McMurray, JJV; Olivier, A; Pitt, B; Pizard, A; Pocock, SJ; Rossignol, P; Swedberg, K; van Veldhuisen, DJ; Zannad, F | 1 |
| He, JQ; Liang, LJ; Liu, BB; Ma, XL; Shimosawa, T; Wang, CH; Wang, XT; Wang, Z; Xu, QY | 1 |
| Chadwick, JA; Gomez-Sanchez, CE; Gomez-Sanchez, EP; Hauck, JS; Rafael-Fortney, JA | 1 |
| Arias, SCA; Breyer, MD; Fanelli, C; Fujihara, CK; Jadhav, PK; Kowala, MC; Krieger, JE; Malheiros, DM; Montrose-Rafizadeh, C; Rodrigues, MV; Sena, CR; Zatz, R | 1 |
| Basquin, D; Hullin, R; Maillard, M; Martin, D; Métrich, M; Regamey, J; Sarre, A | 1 |
| Gong, H; Li, H; Lu, Y; Ma, X; Wang, B; Wang, C; Wu, Z; Yan, Y; Zhang, X | 1 |
| Chen, YP; Cheng, H; Dong, HR; Dong, J; Liu, BL; Rui, HL; Yang, M; Zhu, JJ | 1 |
| Aagaard, A; Bamberg, K; Björnson Granqvist, A; Edman, K; Geschwindner, S; Granberg, KL; Gunnarsson, A; Hartleib-Geschwindner, J; Huang, Y; Jaisser, F; Jansson-Löfmark, R; Johansson, U; Myhre, S; William-Olsson, L | 1 |
| Albano, G; Anderegg, M; Fuster, DG; Lang, F; Pathare, G | 1 |
| Aberer, F; Alesutan, I; Bachmann, A; Catena, C; Grübler, MR; März, W; Meinitzer, A; Obermayer-Pietsch, B; Pandis, M; Pilz, S; Schwetz, V; Sechi, LA; Tomaschitz, A; Trummer, C; Verheyen, N; Voelkl, J | 1 |
| Aibara, Y; Chayama, K; Goto, C; Hashimoto, H; Higashi, Y; Kajikawa, M; Kihara, Y; Kishimoto, S; Liao, JK; Maruhashi, T; Matsui, S; Nakashima, A; Noma, K; Oki, K; Takaeko, Y; Yusoff, FM | 1 |
| Adler, GK; Brooks, DL; Garza, AE; Katayama, IA; Pojoga, LH; Romero, JR; Williams, GH | 1 |
| Damsker, JM; Fiorillo, AA; Heier, CR; Hoffman, EP; Mazala, DA; Nagaraju, K; Spurney, CF; Srinivassane, S; Tucker, A; Tully, CB; Uaesoontrachoon, K; Yu, Q | 1 |
| Manolis, AA; Manolis, AS; Manolis, TA; Melita, H | 1 |
| Battaglia, G; Fiorini, F; Granata, A; La Rosa, S; Maccarrone, R; Ocello, A; Randone, S | 1 |
| Bíró, T; Farman, N; Funk, W; Hundt, JE; Langan, EA; Paus, R; Sass, S | 1 |
| Dizaye, K; Mustafa, ZA | 1 |
| Brooks, DL; Pojoga, LH; Tay, CS; Treesaranuwattana, T; Williams, GH; Williams, JS; Wong, KYH | 1 |
| Adler, GK; Baudrand, R; Brooks, D; Garza, AE; Katayama Rangel, IA; Moize, B; Pojoga, LH; Ranjit, S; Romero, JR; Treesaranuwattana, T; Trefts, E; Williams, GH; Yao, TM | 1 |
| Agarwal, A; Cheung, AK | 1 |
| Aono, D; Demura, M; Hashimoto, A; Higashitani, T; Karashima, S; Kometani, M; Konishi, S; Takeda, Y; Yoneda, T | 1 |
| Chayama, K; Goto, C; Han, Y; Harada, T; Hashimoto, H; Higashi, Y; Kajikawa, M; Kihara, Y; Kishimoto, S; Maruhashi, T; Nakashima, A; Oki, K; Takaeko, Y; Yamaji, T; Yusoff, FM | 1 |
| Adler, GK; Green, JAEM; Hornik, ES; Koefoed, AW; Stone, IB; Williams, GH; Williams, JS | 1 |
| Baker, ME; Hyodo, S; Katsu, Y; Lin, X; Oana, S | 1 |
| Bonnard, B; Fernández-Celis, A; Jaisser, F; López-Andrés, N; Nakamura, T; Palacios-Ramirez, R | 1 |
| Aleksiejczuk, M; Chabielska, E; Dzieciol, J; Gromotowicz-Poplawska, A; Marcinczyk, N; Stelmaszewska, J | 1 |
| Chang, Y; Gao, X; Han, Y; Hao, J; Liang, L; Qiang, P; Shimosawa, T; Xian, Y; Xiong, Y; Xu, Q; Yang, F | 1 |
| Ben, Y; Chang, Y; Chen, G; Gao, X; Hao, J; Li, H; Ma, X; Qiang, P; Shimosawa, T; Wang, X; Xiong, Y; Xu, Q; Yang, F | 1 |
| Dragomiretskaya, NA; Kucherova, JS; Podzolkov, VI; Tarzimanova, AI | 1 |
| Brown, JM; Heydarpour, M; Mannstadt, M; Parksook, WW; Turchin, A; Vaidya, A | 1 |
| Chang, Y; Gao, X; Han, Y; Hao, J; Qiang, P; Shimosawa, T; Xian, Y; Xu, Q; Yang, F | 1 |
| Chen, XD; Close, SB; DeLaney, EN; Deng, F; Dick, DM; Dong, YH; Elias, MJ; Hawa, S; Hikasa, Y; Hu, JJ; Kai, M; Li, C; Liu, KX; Lozada, FT; Ohishi, T; Su, J; van Horn, JE; Walker, CJ; Wibbelink, CJM; Williams, CD; Zhao, BC | 1 |
| Caglayan, E; Kmieć, P; Odenthal, M; Rosenkranz, S | 1 |
| Akaihata, H; Hata, J; Honda-Takinami, R; Hoshi, S; Kataoka, M; Kojima, Y; Matsuoka, K; Ogawa, S; Onagi, A; Sato, Y; Tanji, R | 1 |
69 review(s) available for aldosterone and eplerenone
| Article | Year |
|---|---|
The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.
Topics: Aldosterone; Animals; Antihypertensive Agents; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Spironolactone | 2000 |
Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Eplerenone; Humans; Hypertension; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Rats; Rats, Inbred SHR; Spironolactone | 2001 |
Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.
Topics: Aldosterone; Animals; Cardiovascular System; Clinical Trials as Topic; Endothelium, Vascular; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Protective Agents; Receptors, Mineralocorticoid; Renin-Angiotensin System; Spironolactone; Tissue Survival | 2001 |
The pathophysiology of aldosterone in the cardiovascular system.
Topics: Aldosterone; Animals; Brain; Cardiovascular Diseases; Eplerenone; Heart; Humans; Kidney; Mineralocorticoid Receptor Antagonists; Myocardium; Randomized Controlled Trials as Topic; Salts; Spironolactone | 2002 |
New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone.
Topics: Aldosterone; Animals; Cardiomegaly; Clinical Trials as Topic; Desoxycorticosterone; Eplerenone; Fibrosis; Heart; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Myocardium; Rats; Rats, Inbred SHR; Receptors, Mineralocorticoid; Spironolactone | 2002 |
Clinical implications of aldosterone blockade.
Topics: Aldosterone; Antihypertensive Agents; Black People; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Eplerenone; Humans; Hypertension; Kidney Diseases; Losartan; Mineralocorticoid Receptor Antagonists; Potassium; Renin-Angiotensin System; Spironolactone | 2002 |
The role of aldosterone receptor blockade in the management of cardiovascular disease.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2002 |
Eplerenone.
Topics: Aldosterone; Antihypertensive Agents; Clinical Trials as Topic; Drug Approval; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone; United States; United States Food and Drug Administration | 2003 |
[Aldosterone and its antagonists in heart failure].
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Diuretics; Eplerenone; Heart Failure; Homeostasis; Humans; Mineralocorticoid Receptor Antagonists; Multicenter Studies as Topic; Placebos; Randomized Controlled Trials as Topic; Receptors, Mineralocorticoid; Spironolactone; Time Factors | 2003 |
Eplerenone, a new selective aldosterone blocker.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiovascular System; Disease Models, Animal; Dogs; Eplerenone; Heart Injuries; Humans; Kidney Diseases; Mineralocorticoid Receptor Antagonists; Rats; Renin-Angiotensin System; Spironolactone | 2003 |
Aldosterone as a target in congestive heart failure.
Topics: Aldosterone; Cardiovascular Agents; Endothelium, Vascular; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Myocardium; Plasminogen Activator Inhibitor 1; Progesterone; Randomized Controlled Trials as Topic; Spironolactone; Treatment Outcome | 2003 |
Eplerenone: cardiovascular protection.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Cardiovascular System; Disease Models, Animal; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone; Treatment Outcome | 2003 |
Aldosterone resurgens--letter from EPHESUS.
Topics: Aldosterone; Animals; Cardiac Output, Low; Cardiovascular Diseases; Eplerenone; Humans; Inflammation; Metaphor; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Spironolactone | 2003 |
RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease.
Topics: Aldosterone; Cardiovascular Diseases; Eplerenone; Humans; Kidney Diseases; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone | 2003 |
Aldosterone receptor antagonists for hypertension: what do they offer?
Topics: Aldosterone; Clinical Trials as Topic; Diuretics; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Mineralocorticoids; Renin-Angiotensin System; Spironolactone | 2003 |
Aldosterone receptor blockade and the role of eplerenone: evolving perspectives.
Topics: Aldosterone; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Eplerenone; Female; Humans; Male; Mineralocorticoid Receptor Antagonists; Prognosis; Receptors, Mineralocorticoid; Renal Insufficiency; Risk Assessment; Spironolactone; Survival Analysis; Treatment Outcome | 2003 |
Aldosterone blockade in patients with systolic left ventricular dysfunction.
Topics: Aldosterone; Eplerenone; Forecasting; Heart Failure; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Patient Selection; Randomized Controlled Trials as Topic; Spironolactone; Systole; Ventricular Dysfunction, Left | 2003 |
Review of aldosterone- and angiotensin II-induced target organ damage and prevention.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiovascular Diseases; Endothelium, Vascular; Eplerenone; Humans; Kidney; Mineralocorticoid Receptor Antagonists; Myocardium; Spironolactone | 2004 |
[Significance of aldosterone antagonist therapy].
Topics: Aldosterone; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Eplerenone; Heart Failure; Hemodynamics; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Receptors, Mineralocorticoid; Spironolactone; Water-Electrolyte Balance | 2004 |
The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade.
Topics: Aldosterone; Autonomic Nervous System Diseases; Endomyocardial Fibrosis; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Vascular Diseases; Water-Electrolyte Imbalance | 2004 |
Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone | 2004 |
Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Digoxin; Enzyme Inhibitors; Eplerenone; Female; Humans; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Randomized Controlled Trials as Topic; Spironolactone; Systole; Ventricular Dysfunction, Left | 2004 |
Towards selectively modulating mineralocorticoid receptor function: lessons from other systems.
Topics: Aldosterone; Anti-Inflammatory Agents; Crystallography, X-Ray; Epithelium; Eplerenone; Hydrocortisone; Mineralocorticoid Receptor Antagonists; Myocytes, Cardiac; Protein Binding; Protein Structure, Tertiary; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Receptors, Thyroid Hormone; Signal Transduction; Spironolactone; Structure-Activity Relationship | 2004 |
Aldosterone target organ protection by eplerenone.
Topics: Aldosterone; Blood Vessels; Brain; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; Receptors, Mineralocorticoid; Spironolactone; Vasculitis, Central Nervous System; Ventricular Remodeling | 2004 |
Eplerenone in the treatment of chronic heart failure.
Topics: Aldosterone; Chronic Disease; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone; Treatment Outcome | 2004 |
The role of aldosterone and aldosterone-receptor antagonists in heart failure.
Topics: Aldosterone; Eplerenone; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardium; Spironolactone | 2004 |
Mineralocorticoid receptor antagonists and hypertension: is there a rationale?
Topics: Albuminuria; Aldosterone; Animals; Drug Therapy, Combination; Eplerenone; Humans; Hyperkalemia; Hypertension; Hypertrophy, Left Ventricular; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone; Vasodilation | 2004 |
The clinical implications of aldosterone escape in congestive heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Death, Sudden, Cardiac; Endothelium, Vascular; Eplerenone; Fibrosis; Heart Failure; Humans; Myocardium; Spironolactone; Ventricular Remodeling | 2004 |
Eplerenone: a new selective aldosterone receptor antagonist.
Topics: Aldosterone; Animals; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Spironolactone | 2004 |
[Aldosterone antagonist therapy for chronic heart failure].
Topics: Aldosterone; Chronic Disease; Death, Sudden, Cardiac; Diuretics; Eplerenone; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardium; Randomized Controlled Trials as Topic; Spironolactone; Sulfonamides; Torsemide; Ventricular Remodeling | 2005 |
Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist.
Topics: Aldosterone; Animals; Drug Interactions; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2004 |
[Roll of aldosterone in pathogenesis of kidney disorders].
Topics: Aldosterone; Animals; Body Water; Disease Models, Animal; Eplerenone; Humans; Hypertension; Kidney Diseases; Mineralocorticoid Receptor Antagonists; Potassium; Proteinuria; Receptors, Mineralocorticoid; Sodium; Spironolactone | 2005 |
Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
Topics: Aldosterone; Animals; Eplerenone; Heart Failure; Hypertension; Ligands; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Spironolactone; Transcription, Genetic | 2005 |
[Recent insights into the role of aldosterone in physiology, pathology and therapy].
Topics: Aldosterone; Cardiovascular Diseases; Eplerenone; Humans; Spironolactone | 2005 |
Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade.
Topics: Aldosterone; Animals; Cell Proliferation; Cell Shape; Cells, Cultured; Collagen; Eplerenone; Fibroblasts; Fibrosis; Humans; Kidney; Kidney Diseases; Mesangial Cells; Mineralocorticoid Receptor Antagonists; Mitogen-Activated Protein Kinases; Rats; Reactive Oxygen Species; Receptors, Mineralocorticoid; Spironolactone | 2006 |
Mineralocorticoid receptor blockade in the protection of target organ damage.
Topics: Aldosterone; Animals; Brain; Brain Diseases; Cardiovascular Diseases; Eplerenone; Heart; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2006 |
[Cardiovascular action of aldosterone].
Topics: Aldosterone; Animals; Cardiovascular Diseases; Endothelium, Vascular; Epithelial Sodium Channels; Eplerenone; Fibrosis; Humans; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Myocardium; Oxidative Stress; Receptors, Mineralocorticoid; Sodium Channels; Sodium-Potassium-Exchanging ATPase; Sodium, Dietary; Spironolactone | 2006 |
[Cardioprotective effect of aldosterone antagonists for ventricular remodeling].
Topics: Aldosterone; Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Reactive Oxygen Species; Receptors, Mineralocorticoid; Spironolactone; Ventricular Remodeling | 2006 |
Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.
Topics: Aldosterone; Algorithms; Disease Progression; Disease Susceptibility; Drug Labeling; Eplerenone; Fibrosis; Heart Failure; Humans; Hyperkalemia; Kidney; Mineralocorticoid Receptor Antagonists; Renal Agents; Renal Insufficiency; Spironolactone | 2006 |
[Aldosterone antagonists: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Topics: Aldosterone; Chronic Disease; Contraindications; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Prognosis; Randomized Controlled Trials as Topic; Spironolactone; Survival Rate | 2007 |
Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.
Topics: Aldosterone; Contraindications; Drug Therapy, Combination; Eplerenone; Heart Failure; Humans; Hypertension; Kaplan-Meier Estimate; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Spironolactone | 2007 |
[Role of aldosterone in oxidative stress and renal injury].
Topics: Aldosterone; Animals; Cardiovascular Diseases; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; Oxidative Stress; Rats; Reactive Oxygen Species; Receptors, Mineralocorticoid; Renal Insufficiency; Spironolactone | 2007 |
[Molecular mechanism of cardiovascular damage induced by aldosterone].
Topics: Aldosterone; Animals; Biopterins; Cardiovascular Diseases; Cells, Cultured; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphoprotein Phosphatases; Reactive Oxygen Species; Receptors, Mineralocorticoid; Spironolactone | 2007 |
Mineralocorticoid receptor antagonists and endothelial function.
Topics: Aldosterone; Animals; Endocrine System Diseases; Endothelium, Vascular; Eplerenone; Humans; Hyperaldosteronism; Mineralocorticoid Receptor Antagonists; Spironolactone | 2008 |
Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury.
Topics: Aldosterone; Animals; Eplerenone; Humans; Kidney; Kidney Diseases; Mitogen-Activated Protein Kinases; Reactive Oxygen Species; Receptors, Mineralocorticoid; rho-Associated Kinases; Spironolactone | 2008 |
Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension.
Topics: Aldosterone; Animals; Disease Models, Animal; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Rats; Rats, Inbred Dahl; Sodium Chloride; Spironolactone | 2009 |
Aldosterone-receptor antagonism in hypertension.
Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Cardiac; Drug Therapy, Combination; Electrocardiography; Eplerenone; Fibrosis; Glomerular Filtration Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Mineralocorticoid Receptor Antagonists; Myocardium; Spironolactone | 2009 |
Blocking aldosterone in heart failure.
Topics: Aldosterone; Cardiovascular Agents; Drug Therapy, Combination; Eplerenone; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardium; Spironolactone; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling | 2009 |
[Chronic kidney disease and the aldosterone/mineralocorticoid receptor system].
Topics: Aldosterone; Animals; Chronic Disease; Eplerenone; Humans; Kidney Diseases; Metabolic Syndrome; Mineralocorticoid Receptor Antagonists; Podocytes; Proteinuria; Receptors, Mineralocorticoid; Risk Factors; Spironolactone | 2010 |
Mineralocorticoid receptor antagonists and the metabolic syndrome.
Topics: Aldosterone; Antihypertensive Agents; Eplerenone; Humans; Hypertension; Inflammation; Insulin Resistance; Lipid Metabolism; Lipids; Metabolic Syndrome; Mineralocorticoid Receptor Antagonists; Obesity; Signal Transduction; Spironolactone | 2010 |
[Prothrombotic aldosterone action--a new side of the hormone].
Topics: Aldosterone; Animals; Eplerenone; Hemostasis; Platelet Adhesiveness; Rats; Spironolactone; Thrombosis | 2010 |
Aldosterone antagonists in heart failure.
Topics: Aldosterone; Animals; Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Patient Selection; Severity of Illness Index; Spironolactone | 2011 |
Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney.
Topics: Aldosterone; Animals; Blood Pressure; Electrolytes; Eplerenone; Homeostasis; Humans; Kidney; Kidney Diseases; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Rats; Receptors, Mineralocorticoid; Renal Circulation; Spironolactone | 2011 |
Aldosterone stimulates nuclear factor-kappa B activity and transcription of intercellular adhesion molecule-1 and connective tissue growth factor in rat mesangial cells via serum- and glucocorticoid-inducible protein kinase-1.
Topics: Aldosterone; Animals; Connective Tissue Growth Factor; Eplerenone; Glomerulonephritis; I-kappa B Proteins; Immediate-Early Proteins; Intercellular Adhesion Molecule-1; Kidney; MAP Kinase Kinase 1; Mesangial Cells; Mineralocorticoid Receptor Antagonists; NF-kappa B; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Rats; Spironolactone | 2012 |
Mineralocorticoid receptor antagonists for heart failure.
Topics: Aldosterone; Animals; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Spironolactone; Treatment Outcome | 2011 |
Eplerenone for the treatment of cardiovascular disorders.
Topics: Aldosterone; Animals; Cardiovascular Agents; Cardiovascular Diseases; Eplerenone; Humans; Hydrocortisone; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Spironolactone | 2012 |
[Primay hyperaldosteronism--diagnostic and treatment].
Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenal Hyperplasia, Congenital; Adrenocortical Adenoma; Aldosterone; Antihypertensive Agents; Diagnosis, Differential; Eplerenone; Hyperaldosteronism; Hypertension; Hypokalemia; Magnetic Resonance Imaging; Mass Screening; Renin; Spironolactone; Tomography, X-Ray Computed | 2012 |
Endocrine and hypertensive disorders of potassium regulation: primary aldosteronism.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Adenoma; Aldosterone; Eplerenone; Humans; Hyperaldosteronism; Hypertension; Hypokalemia; Mineralocorticoid Receptor Antagonists; Renin; Spironolactone | 2013 |
Aldosterone and volume management in hypertensive heart disease.
Topics: Aldosterone; Area Under Curve; Diuretics; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Renal Insufficiency, Chronic; Spironolactone | 2014 |
[Hypertension in the course of primary aldosteronism during pregnancy].
Topics: Acid Sensing Ion Channel Blockers; Aldosterone; Amiloride; Antihypertensive Agents; Eplerenone; Female; Humans; Hyperaldosteronism; Hypertension; Poland; Pregnancy; Pregnancy Complications; Progesterone; Spironolactone | 2015 |
Pharmacological treatment of aldosterone excess.
Topics: Aldosterone; Cytochrome P-450 CYP11B2; Dihydropyridines; Drug Interactions; Epithelial Sodium Channel Blockers; Eplerenone; Glucocorticoids; Heart Failure; Hyperaldosteronism; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2015 |
Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
Topics: Aldosterone; Drug Interactions; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Spironolactone | 2015 |
Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis.
Topics: Aldosterone; Atrial Fibrillation; Cardiac Surgical Procedures; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Spironolactone | 2016 |
Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety.
Topics: Aldosterone; Blood Pressure; Disease Progression; Eplerenone; Heart Failure; Humans; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Patient Safety; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Spironolactone; Stroke Volume; Survival Analysis; Treatment Outcome; Ventricular Remodeling | 2016 |
Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences.
Topics: Aldosterone; Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2016 |
Synthetic approaches towards the multi target drug spironolactone and its potent analogues/derivatives.
Topics: Aldosterone; Androstadienes; Androstenes; Animals; Canrenone; Chloranil; Dehydroepiandrosterone; Eplerenone; Humans; Molecular Structure; Receptors, Mineralocorticoid; Spironolactone | 2017 |
Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?
Topics: Aldosterone; Antihypertensive Agents; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2019 |
[Antifibrotic renal role of mineralcorticoid receptor antagonists].
Topics: Aldosterone; Body Fluids; Cardiovascular Diseases; Clinical Trials as Topic; Cytokines; Diabetic Nephropathies; Eplerenone; Fibrosis; Heart; Heart Diseases; Homeostasis; Humans; Kidney; Mineralocorticoid Receptor Antagonists; Naphthyridines; Receptors, Mineralocorticoid; Renal Insufficiency, Chronic; Spironolactone | 2019 |
Topics: Aldosterone; Animals; Antihypertensive Agents; Cat Diseases; Cats; Eplerenone; Renal Insufficiency, Chronic; Retrospective Studies | 2022 |
12 trial(s) available for aldosterone and eplerenone
| Article | Year |
|---|---|
Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.
Topics: Adult; Aldosterone; Analysis of Variance; Angiotensin Receptor Antagonists; Antihypertensive Agents; Black People; Blood Pressure; Double-Blind Method; Eplerenone; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Renin; Renin-Angiotensin System; Spironolactone; Treatment Outcome; White People | 2003 |
Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
Topics: Aldosterone; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Eplerenone; Female; Heart Rate; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Potassium; Renin; Spironolactone | 2003 |
Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction.
Topics: Aldosterone; Biomarkers; Double-Blind Method; Echocardiography; Electrocardiography; Eplerenone; Female; Follow-Up Studies; Heart Ventricles; Humans; Hydrocortisone; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Prospective Studies; Spironolactone; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling | 2011 |
The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism.
Topics: Adult; Aldosterone; Animals; Area Under Curve; Biomarkers; Cell Line, Tumor; Eplerenone; Humans; Male; Mineralocorticoid Receptor Antagonists; Potassium; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Sodium; Spironolactone; Time Factors; Translational Research, Biomedical; Young Adult | 2011 |
Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease.
Topics: Aldosterone; Confidence Intervals; Double-Blind Method; Eplerenone; Female; Health Status Indicators; Heart Failure; Humans; Kidney Failure, Chronic; Male; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Research Design; Severity of Illness Index; Spironolactone | 2012 |
Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist.
Topics: Aged; Albuminuria; Aldosterone; Amides; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eplerenone; Female; Fumarates; Humans; Hypertension; Incidence; Longitudinal Studies; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Renin; Renin-Angiotensin System; Spironolactone; Time Factors | 2013 |
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.
Topics: Adult; Aldosterone; Cardiac Imaging Techniques; Collagen; Double-Blind Method; Eplerenone; Female; Fibrosis; Follow-Up Studies; Heart Failure; Humans; Magnetic Resonance Imaging; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Spironolactone; Transposition of Great Vessels; Treatment Outcome; Ventricular Dysfunction, Right; Young Adult | 2013 |
A pilot study of the effects of eplerenone add-on therapy in patients taking renin-angiotensin system blockers.
Topics: Adult; Aged; Albuminuria; Aldosterone; Blood Pressure; Diastole; Eplerenone; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Pilot Projects; Renin-Angiotensin System; Spironolactone; Systole | 2015 |
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial.
Topics: Aged; Aldosterone; Drug Monitoring; Eplerenone; Female; Heart Failure, Systolic; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Obesity, Abdominal; Spironolactone; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2017 |
Mineralocorticoid Receptor Blockers and Aldosterone to Renin Ratio: A Randomized Controlled Trial and Observational Data.
Topics: Aged; Aldosterone; Double-Blind Method; Eplerenone; Female; Humans; Hyperaldosteronism; Hyperparathyroidism; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Renin; Spironolactone; Time Factors | 2018 |
Striatin genotype-based, mineralocorticoid receptor antagonist-driven clinical trial: study rationale and design.
Topics: Adolescent; Adult; Aged; Aldosterone; Alleles; Amlodipine; Animals; Blood Pressure; Calmodulin-Binding Proteins; Clinical Trials as Topic; Eplerenone; Genetic Predisposition to Disease; Humans; Hypertension; Male; Membrane Proteins; Mice; Middle Aged; Mineralocorticoid Receptor Antagonists; Nerve Tissue Proteins; Polymorphism, Single Nucleotide; Receptors, Mineralocorticoid; Young Adult | 2021 |
Evaluating the clinical and mechanistic effects of eplerenone and amiloride monotherapy, and combination therapy with cinacalcet, in primary hyperparathyroidism: A placebo-controlled randomized trial.
Topics: Aldosterone; Amiloride; Calcium; Cinacalcet; Eplerenone; Female; Humans; Hyperparathyroidism, Primary; Male; Parathyroid Hormone; Renin | 2023 |
182 other study(ies) available for aldosterone and eplerenone
| Article | Year |
|---|---|
Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.
Topics: Amino Acid Sequence; Animals; Benzoxazines; Dihydropyridines; Drug Discovery; Humans; Ligands; Macrolides; Mineralocorticoid Receptor Antagonists; Models, Molecular; Oxazolidinones; Peptides; Pyrazoles; Pyrroles; Receptors, Mineralocorticoid; Structure-Activity Relationship; Sulfonamides | 2017 |
The memory-facilitating effects of the competitive NMDA-receptor antagonist CGP 37849 are steroid-sensitive, whereas its memory-impairing effects are not.
Topics: 2-Amino-5-phosphonovalerate; Aldosterone; Aminoglutethimide; Animals; Corticosterone; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Male; Memory; Mice; Mineralocorticoid Receptor Antagonists; Spironolactone | 1996 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibitors; Eplerenone; Hormone Antagonists; Kidney; Male; Myocardium; Necrosis; NG-Nitroarginine Methyl Ester; Rats; Rats, Wistar; Renal Artery; Renin; Sodium Chloride; Spironolactone; Vascular Diseases | 2000 |
Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries.
Topics: Aldosterone; Angioplasty, Balloon; Animals; Collagen; Constriction, Pathologic; Coronary Disease; Coronary Vessels; Elastin; Eplerenone; Iliac Artery; Male; Mineralocorticoid Receptor Antagonists; Spironolactone; Swine; Swine, Miniature; Tunica Intima | 2001 |
New treasures from old? EPHESUS. Eplerenome Post-AHI Heart Failure Efficacy and Survival Study.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone | 2001 |
The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
Topics: Aldosterone; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Multicenter Studies as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Research Design; Sample Size; Spironolactone; Survival Analysis; Systole | 2001 |
Aldosterone 2001.
Topics: Aldosterone; Alternative Splicing; Body Composition; Calcium Channels; Epithelial Sodium Channels; Eplerenone; Glycyrrhiza; Humans; Phosphatidylinositol 3-Kinases; Plasminogen Activator Inhibitor 1; Receptors, Cytoplasmic and Nuclear; Receptors, Mineralocorticoid; Sodium Channels; Spironolactone; Transcription Factors; Vasopressins | 2001 |
Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading.
Topics: Aldosterone; Angiotensin II; Animals; Diet, Sodium-Restricted; Disease Models, Animal; Eplerenone; Heart Diseases; Male; Mineralocorticoid Receptor Antagonists; NG-Nitroarginine Methyl Ester; Potassium; Rats; Rats, Wistar; Spironolactone | 2002 |
Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form.
Topics: Aldosterone; Animals; Dogs; Eplerenone; Female; Injections, Intravenous; Lactones; Models, Animal; Spironolactone | 2002 |
Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Eplerenone; Heart Ventricles; Hyperaldosteronism; Losartan; Magnesium; Male; Membrane Potentials; Mineralocorticoid Receptor Antagonists; Patch-Clamp Techniques; Potassium; Rabbits; Sodium; Sodium-Potassium-Exchanging ATPase; Spironolactone; Ventricular Function | 2002 |
Aldosterone induces a vascular inflammatory phenotype in the rat heart.
Topics: Aldosterone; Animals; Blood Pressure; Chemokine CCL2; Coronary Vessels; Cyclooxygenase 2; Endomyocardial Fibrosis; Eplerenone; Gene Expression; Hypertension; Immunohistochemistry; In Situ Hybridization; Intercellular Adhesion Molecule-1; Isoenzymes; Male; Myocardium; Osteopontin; Phenotype; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Sprague-Dawley; Sialoglycoproteins; Spironolactone; Vascular Cell Adhesion Molecule-1; Vasculitis | 2002 |
[Selective aldosterone blocker for hypertension and heart failure. Better tolerance than previous drugs].
Topics: Aldosterone; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hypertension; Spironolactone | 2002 |
Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Body Weight; Coronary Disease; Coronary Vessels; Corticosterone; Cyclooxygenase 2; Diuresis; Drinking; Eating; Eplerenone; Heart; Hypertension; Isoenzymes; Macrophages; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Necrosis; Organ Size; Osteopontin; Potassium; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Wistar; Renin; Sialoglycoproteins; Sodium; Sodium Chloride; Spironolactone; Vasculitis | 2002 |
Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone.
Topics: Aldosterone; Animals; Blood Pressure; Blotting, Northern; Carotid Arteries; Collagen; Collagen Type I; Collagen Type III; Disease Models, Animal; Dose-Response Relationship, Drug; Elasticity; Elastin; Eplerenone; Fibronectins; Hyperaldosteronism; Immunohistochemistry; Injections, Subcutaneous; Male; Mineralocorticoid Receptor Antagonists; Nephrectomy; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sodium, Dietary; Spironolactone; Ultrasonography; Vascular Patency | 2002 |
Nongenomic effect of aldosterone on Na+,K+-adenosine triphosphatase in arterial vessels.
Topics: Aldosterone; Animals; Aorta, Thoracic; Catalytic Domain; Cycloheximide; Dactinomycin; Enzyme Inhibitors; Eplerenone; Indoles; Ionophores; Male; Maleimides; Mineralocorticoid Receptor Antagonists; Monensin; Protein Biosynthesis; Protein Kinase C; Protein Synthesis Inhibitors; Rats; Rats, Sprague-Dawley; Sodium; Sodium-Potassium-Exchanging ATPase; Spironolactone; Transcription, Genetic | 2003 |
Aldosterone blockade and heart failure.
Topics: Aldosterone; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone; Ventricular Dysfunction, Left | 2003 |
Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats.
Topics: Aldosterone; Animals; Blood Pressure; Cytokines; Eplerenone; Fibrosis; Hypertension, Renal; Immunohistochemistry; In Situ Hybridization; Kidney; Macrophages; Male; Nephritis; Rats; Rats, Sprague-Dawley; Sodium Chloride; Spironolactone | 2003 |
Hypertension, angiotensin II, aldosterone, and race.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Antihypertensive Agents; Black People; Eplerenone; Humans; Hypertension; Losartan; Mineralocorticoid Receptor Antagonists; Renin; Renin-Angiotensin System; Spironolactone; Treatment Outcome; White People | 2003 |
Aldosterone antagonism and hypertension.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Physiological Phenomena; Cardiovascular System; Drug Therapy, Combination; Eplerenone; Humans; Hypertension; Peptidyl-Dipeptidase A; Renin-Angiotensin System; Spironolactone; Treatment Outcome | 2003 |
Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice.
Topics: Aldosterone; Animals; Apolipoproteins E; Arteriosclerosis; Aryldialkylphosphatase; Blood Pressure; Eplerenone; Free Radical Scavengers; Lipid Peroxidation; Lipids; Macrophages, Peritoneal; Mice; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Spironolactone; Superoxides; Time Factors | 2003 |
Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Disease Models, Animal; Echocardiography; Eplerenone; Female; Fibrosis; Gene Expression Regulation; Gene Expression Regulation, Enzymologic; Heart Failure; Hydroxysteroid Dehydrogenases; Kidney; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mineralocorticoid Receptor Antagonists; Myocardium; Myocytes, Cardiac; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Up-Regulation; Ventricular Dysfunction, Left | 2003 |
[Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement].
Topics: Aldosterone; Clinical Trials as Topic; Eplerenone; Germany; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Survival Rate; Treatment Outcome; Ventricular Dysfunction, Left | 2003 |
Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats.
Topics: Aldosterone; Animals; Cyclic N-Oxides; Eplerenone; Hypertension; JNK Mitogen-Activated Protein Kinases; Kidney Cortex; Male; MAP Kinase Signaling System; Membrane Transport Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 7; Mitogen-Activated Protein Kinases; NADPH Dehydrogenase; NADPH Oxidase 4; NADPH Oxidases; Oxidative Stress; Phosphoproteins; Proteinuria; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Sodium Chloride; Spin Labels; Spironolactone | 2004 |
Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
Topics: Acetylcholine; Aldosterone; Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Collagen; Dose-Response Relationship, Drug; Endothelium, Vascular; Eplerenone; Fibrosis; Heart; Hydralazine; Hypertension; Male; Mesenteric Arteries; Mineralocorticoid Receptor Antagonists; Myocardium; Natriuresis; Organ Size; Rats; Rats, Inbred SHR; Receptors, Mineralocorticoid; Sodium Chloride, Dietary; Spironolactone; Thiobarbituric Acid Reactive Substances; Tunica Media; Vasodilation | 2004 |
Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aortic Diseases; Apolipoproteins E; Arteriosclerosis; Cell Line; Enzyme Induction; Eplerenone; Hormone Antagonists; Humans; Lipid Peroxidation; Lipoproteins, LDL; Losartan; Macrophages, Peritoneal; Membrane Proteins; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; Oxidative Stress; Peptidyl-Dipeptidase A; Phosphoproteins; Protein Transport; Ramipril; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; RNA, Messenger; Spironolactone; Superoxides | 2004 |
Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy.
Topics: Aldosterone; Angiotensin II; Animals; Apoptosis; Blood Pressure; Cardiomegaly; Cell Size; Eplerenone; Fibrosis; Heart Rate; Hypertrophy, Left Ventricular; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Myocytes, Cardiac; Osteopontin; Reverse Transcriptase Polymerase Chain Reaction; Sialoglycoproteins; Spironolactone; Ultrasonography; Ventricular Remodeling | 2004 |
The discovery, isolation and identification of aldosterone: reflections on emerging regulation and function.
Topics: Aldosterone; Angiotensins; Biological Assay; Clinical Trials as Topic; Eplerenone; History, 20th Century; Humans; Proteins; Spironolactone; Technology, Pharmaceutical | 2004 |
The evolution of aldosterone antagonists.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Clinical Trials as Topic; Eplerenone; Gynecomastia; History, 20th Century; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2004 |
Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels.
Topics: Aldosterone; Androstadienes; Animals; Blotting, Western; Calcium; Chromones; Enzyme Inhibitors; Eplerenone; Flavonoids; Hydrogen-Ion Concentration; Indoles; Male; Maleimides; Mesenteric Arteries; Mineralocorticoid Receptor Antagonists; Morpholines; p38 Mitogen-Activated Protein Kinases; Phenylephrine; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase C; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Spironolactone; Time Factors; Vasoconstriction; Wortmannin | 2005 |
Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.
Topics: Aldosterone; Animals; Chlorocebus aethiops; COS Cells; Crystallization; Eplerenone; Kinetics; Ligands; Mineralocorticoid Receptor Antagonists; Models, Molecular; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Spironolactone | 2004 |
The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms.
Topics: Aldosterone; Amino Acid Motifs; Amino Acid Sequence; Cell Line; Cells, Cultured; Dose-Response Relationship, Drug; Eplerenone; Fluorescence Resonance Energy Transfer; Gene Expression Regulation; Glucocorticoids; Humans; Hydrocortisone; Ligands; Models, Biological; Molecular Sequence Data; Mutation; Peptides; Protein Binding; Protein Conformation; Protein Structure, Tertiary; Receptors, Mineralocorticoid; Sequence Homology, Amino Acid; Spironolactone; Transcription, Genetic; Transfection | 2005 |
[Aldosterone and aldosterone antagonists. Eplerenone in cardiac insufficiency after myocardial infarction].
Topics: Aldosterone; Cardiac Output, Low; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone | 2005 |
Participation of aldosterone in the vascular inflammatory response of spontaneously hypertensive rats: role of the NFkappaB/IkappaB system.
Topics: Aldosterone; Animals; Antihypertensive Agents; Drug Therapy, Combination; Eplerenone; Hypertension; I-kappa B Proteins; Interleukin-1; Interleukin-6; Male; Mineralocorticoid Receptor Antagonists; NF-kappa B; Rats; Rats, Inbred SHR; Rats, Inbred WKY; RNA, Messenger; Spironolactone; Tumor Necrosis Factor-alpha; Vasculitis | 2005 |
Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Aldosterone; Animals; Calcium-Calmodulin-Dependent Protein Kinases; Cell Proliferation; Cells, Cultured; Cycloheximide; Enzyme Activation; Eplerenone; Flavonoids; Genes, Dominant; MAP Kinase Kinase 5; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 7; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Protein Synthesis Inhibitors; Rats; Receptors, Mineralocorticoid; Spironolactone; Transfection | 2005 |
Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients.
Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme 2; Animals; Carboxypeptidases; Eplerenone; Heart Failure; Humans; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Middle Aged; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; Oxidative Stress; Peptidyl-Dipeptidase A; Renin-Angiotensin System; Spironolactone | 2005 |
Eplerenone antagonizes atherosclerosis, but what is the agonist?
Topics: Aldosterone; Animals; Atherosclerosis; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Spironolactone | 2005 |
Mechanisms for nongenomic and genomic effects of aldosterone on Na+/H+ exchange in vascular smooth muscle cells.
Topics: Aldosterone; Amiloride; Animals; Cells, Cultured; Eplerenone; Fluorescent Dyes; Genome; Hydrogen-Ion Concentration; Ion Transport; Kinetics; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Rats; Sodium-Hydrogen Exchangers; Spironolactone | 2005 |
Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium.
Topics: Aldosterone; Amides; Animals; Benzofurans; Cells, Cultured; Eplerenone; Hemodynamics; Hypertrophy; Indoles; Leucine; Mineralocorticoid Receptor Antagonists; Myocytes, Cardiac; Phthalic Acids; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Sodium; Sodium-Hydrogen Exchangers; Spironolactone; Time Factors | 2006 |
Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation.
Topics: Aldosterone; Animals; Aorta; Atherosclerosis; Blood Pressure; Cells, Cultured; Chemokine CCL2; Cholesterol, Dietary; Diet, Atherogenic; Enzyme Activation; Eplerenone; Inflammation; Male; Mice; Muscle, Smooth, Vascular; NADPH Oxidases; Oxidative Stress; Spironolactone; Superoxides; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2006 |
Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone?
Topics: Aldosterone; Animals; Cardiotonic Agents; Drug Interactions; Eplerenone; Heart; Hemodynamics; In Vitro Techniques; Kinetics; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardial Ischemia; Myocardium; Rats; Rats, Wistar; Spironolactone | 2006 |
Protective effect of spironolactone on endothelial cell apoptosis.
Topics: Aldosterone; Apoptosis; Blotting, Western; Caspase 3; Caspases; Cell Nucleus; Cell Survival; Cells, Cultured; Cytochromes c; Cytosol; Dexamethasone; Dihydrotestosterone; Endothelial Cells; Enzyme Activation; Eplerenone; Humans; Hydrocortisone; Mineralocorticoid Receptor Antagonists; Mitochondria; Nitric Oxide; Nitric Oxide Synthase; Poly(ADP-ribose) Polymerases; Receptors, Progesterone; Spironolactone; Time Factors; Umbilical Veins | 2006 |
Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
Topics: Aldosterone; Animals; Cardiac Output, Low; Cardiomegaly; Cardiotonic Agents; Coronary Vessels; Corticosterone; Echocardiography; Eplerenone; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Osmolar Concentration; Oxidative Stress; Peptidyl-Dipeptidase A; Rats; Rats, Inbred Dahl; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Renin; RNA, Messenger; Spironolactone; Vasculitis; Ventricular Function; Ventricular Remodeling | 2006 |
Mineralocorticoid receptors and cardiovascular damage: it's not just aldosterone.
Topics: Aldosterone; Animals; Cardiac Output, Low; Cardiomegaly; Cardiotonic Agents; Corticosterone; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Renin; Spironolactone; Ultrasonography | 2006 |
Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in dahl salt-sensitive rats.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxidants; Blood Pressure; Cyclic N-Oxides; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Enalapril; Eplerenone; Epoprostenol; Hypertension; Male; Nitric Oxide; Oxidative Stress; Rats; Rats, Inbred Dahl; Sodium Chloride; Spin Labels; Spironolactone; Treatment Outcome | 2006 |
The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats.
Topics: Actins; Aldosterone; Animals; Blotting, Western; Cytochrome P-450 CYP11B2; Drug Therapy, Combination; Eplerenone; Fibrosis; Heart Failure; Heart Ventricles; Hypertension; Immunohistochemistry; Male; Mineralocorticoid Receptor Antagonists; NF-kappa B; NG-Nitroarginine Methyl Ester; Nitric Oxide; Peptide Fragments; Proliferating Cell Nuclear Antigen; Protein Precursors; Random Allocation; Rats; Rats, Inbred WKY; Receptors, Mineralocorticoid; RNA, Messenger; Spironolactone; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2006 |
Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Eplerenone; Heart; Hypertrophy; Male; Mice; Mice, Knockout; Myocardium; Spironolactone; Ventricular Remodeling | 2006 |
Mineralocorticoid-receptor blockade, hypertension and heart failure.
Topics: Aldosterone; Clinical Trials as Topic; Eplerenone; Heart Failure; Hormone Antagonists; Humans; Hyperkalemia; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2005 |
Rapid effects of aldosterone on clonal human vascular smooth muscle cells.
Topics: Aldosterone; Aorta, Thoracic; Cell Line; Clone Cells; Eplerenone; Estradiol; Humans; Hydrocortisone; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Myosin Light Chains; Phosphatidylinositol 3-Kinases; Phosphorylation; Signal Transduction; Spironolactone; Vasoconstriction; Vasoconstrictor Agents | 2007 |
Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism.
Topics: Administration, Oral; Aldosterone; Clinical Trials as Topic; Eplerenone; Gynecomastia; Humans; Hyperaldosteronism; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Renin; Sex Factors; Spironolactone | 2007 |
Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.
Topics: Aldosterone; Angiotensin II; Animals; Blotting, Western; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP11B2; Diastole; Eplerenone; Heart Failure; Heart Ventricles; Male; Mass Spectrometry; Mineralocorticoid Receptor Antagonists; Myocardial Contraction; Myocardium; Rats; Rats, Inbred Dahl; Receptors, Mineralocorticoid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Steroids; Stroke Volume; Ventricular Function, Left | 2007 |
Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors.
Topics: Adipocytes; Adrenal Glands; Aldosterone; Animals; Cyclic N-Oxides; Disease Models, Animal; Eplerenone; Immediate-Early Proteins; Kidney Failure, Chronic; Male; Metabolic Syndrome; Mineralocorticoid Receptor Antagonists; Obesity; Podocytes; Protein Serine-Threonine Kinases; Protein Synthesis Inhibitors; Proteinuria; Rats; Rats, Inbred SHR; Receptors, Mineralocorticoid; RNA, Messenger; Spin Labels; Spironolactone | 2006 |
Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats.
Topics: Aldosterone; Animals; Cardiomegaly; Diet, Sodium-Restricted; Echocardiography; Eplerenone; Fibrosis; Food-Drug Interactions; Heart; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Rats; Rats, Wistar; Sodium Chloride; Spironolactone; Ventricular Remodeling | 2006 |
Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.
Topics: Aldosterone; Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Cells, Cultured; Cyclic N-Oxides; Enzyme Activation; Eplerenone; Hydralazine; Immediate-Early Proteins; Infusion Pumps; Kidney; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; Nephrectomy; Oxidative Stress; Podocytes; Protein Serine-Threonine Kinases; Proteinuria; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Spin Labels; Spironolactone; Time Factors; Up-Regulation | 2007 |
Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Blood Vessels; Cyclic N-Oxides; Eplerenone; Gene Expression Regulation; Hypertension; Inflammation Mediators; Male; Models, Biological; Oxidative Stress; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Spin Labels; Spironolactone; Tetrazoles | 2007 |
Antagonistic effects of bone morphogenetic protein-4 and -7 on renal mesangial cell proliferation induced by aldosterone through MAPK activation.
Topics: Aldosterone; Animals; Bone Morphogenetic Protein 4; Bone Morphogenetic Protein 7; Bone Morphogenetic Protein Receptors, Type I; Bone Morphogenetic Proteins; Cell Line; Cell Proliferation; Enzyme Activation; Eplerenone; Extracellular Signal-Regulated MAP Kinases; JNK Mitogen-Activated Protein Kinases; Mesangial Cells; Mice; Mineralocorticoid Receptor Antagonists; Mitogen-Activated Protein Kinases; Mitosis; Phosphorylation; Signal Transduction; Smad6 Protein; Spironolactone; Transforming Growth Factor beta | 2007 |
A German family with glucocorticoid-remediable aldosteronism.
Topics: Adolescent; Aldosterone; Algorithms; Blood Pressure; Dexamethasone; Eplerenone; Female; Germany; Glucocorticoids; Humans; Hydrocortisone; Hyperaldosteronism; Male; Middle Aged; Molecular Sequence Data; Pedigree; Sodium; Spironolactone; Steroid 11-beta-Hydroxylase | 2007 |
Interactions between aldosterone and connective tissue growth factor in vascular and renal damage in spontaneously hypertensive rats.
Topics: Aldosterone; Animals; Aorta; Blood Pressure; Blood Pressure Determination; Cells, Cultured; Connective Tissue Growth Factor; Eplerenone; Hypertension; Immediate-Early Proteins; Immunohistochemistry; Intercellular Signaling Peptides and Proteins; Kidney Glomerulus; Kidney Tubules; Male; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Spironolactone; Up-Regulation | 2007 |
Dose-dependent endothelial cell growth and stiffening by aldosterone: endothelial protection by eplerenone.
Topics: Aldosterone; Cell Enlargement; Cell Line; Cells, Cultured; Coronary Vessels; Dose-Response Relationship, Drug; Elasticity; Endothelial Cells; Eplerenone; Humans; In Vitro Techniques; Microscopy, Atomic Force; Mineralocorticoid Receptor Antagonists; Spironolactone | 2007 |
Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiac Output, Low; Drug Synergism; Eplerenone; Hypertension; Indoles; Kidney; Male; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; Oxidative Stress; Rats; Rats, Inbred Dahl; Reactive Oxygen Species; Sodium-Potassium-Exchanging ATPase; Spironolactone; Superoxide Dismutase; Transforming Growth Factor beta | 2007 |
Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation.
Topics: Aldosterone; Analysis of Variance; Angiotensin II; Animals; Blood Pressure; Body Weight; Cytokines; Disease Models, Animal; Eplerenone; Female; Fibroblasts; Fibrosis; Hypertension; Immunohistochemistry; In Situ Hybridization; Inflammation Mediators; Intercellular Signaling Peptides and Proteins; Macrophages; Mice; Mice, Inbred BALB C; Mineralocorticoid Receptor Antagonists; Myocardium; Reverse Transcriptase Polymerase Chain Reaction; Spironolactone; Tenascin; Up-Regulation; Vasoconstrictor Agents | 2007 |
Acute aldosterone infusion enhances thrombosis development in normotensive rats.
Topics: Aldosterone; Animals; Blood Coagulation; Blood Pressure; Carboxypeptidase B2; Disease Models, Animal; Eplerenone; Infusions, Intravenous; Male; Mineralocorticoid Receptor Antagonists; Plasminogen Activator Inhibitor 1; Rats; Rats, Wistar; Receptors, Mineralocorticoid; Spironolactone; Thromboplastin; Thrombosis; Tissue Plasminogen Activator | 2007 |
Avoiding vicious circles: mineralocorticoid receptor antagonism prevents vascular oxidative stress early after myocardial infarction.
Topics: Aldosterone; Angiotensin II; Animals; Endothelium, Vascular; Eplerenone; Humans; Mice; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Oxidative Stress; Rats; Signal Transduction; Spironolactone | 2007 |
Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress.
Topics: Aldosterone; Animals; Antioxidants; Cyclic N-Oxides; Disease Models, Animal; Eplerenone; Hypertension; Kidney Diseases; Male; Metabolic Syndrome; Obesity; Oxidative Stress; Rats; Rats, Inbred SHR; Rats, Mutant Strains; Receptors, Cell Surface; Receptors, Leptin; Receptors, Mineralocorticoid; Renin; Sodium Chloride, Dietary; Spin Labels; Spironolactone | 2007 |
Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensinogen; Animals; Benzimidazoles; Biphenyl Compounds; Cardiomegaly; Endothelium, Vascular; Eplerenone; Fibrosis; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Peptidyl-Dipeptidase A; Rats; Rats, Inbred Dahl; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; RNA, Messenger; Spironolactone; Tetrazoles | 2007 |
Aldosterone induces superoxide generation via Rac1 activation in endothelial cells.
Topics: Acetophenones; Aldosterone; Animals; Aorta, Thoracic; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Inhibitors; Eplerenone; Male; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; rac1 GTP-Binding Protein; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Spironolactone; Superoxides | 2008 |
Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability.
Topics: Acetylcholine; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta, Thoracic; Atherosclerosis; Biological Availability; Blood Pressure; Cholesterol; Enalapril; Eplerenone; Mineralocorticoid Receptor Antagonists; Nitric Oxide; Peptidyl-Dipeptidase A; Peroxynitrous Acid; Rabbits; Reactive Oxygen Species; Spironolactone | 2008 |
Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response.
Topics: Aldosterone; Animals; Clodronic Acid; Collagen; Cytokines; Eplerenone; Factor XIIIa; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Monocytes; Myocardial Infarction; Myocarditis; Myocardium; Neovascularization, Physiologic; Rats; Rats, Wistar; RNA, Messenger; Spironolactone; Ventricular Function, Left; Wound Healing | 2008 |
Translational research goes both ways: lessons from clinical studies.
Topics: Aldosterone; Amino Acid Sequence; Antihypertensive Agents; Biomedical Research; Clinical Trials as Topic; Corticosterone; Dose-Response Relationship, Drug; Eplerenone; Genetic Predisposition to Disease; Heart Failure; Humans; Hypertension; Receptors, Mineralocorticoid; Spironolactone | 2008 |
Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Benzimidazoles; Biphenyl Compounds; Dimerization; Eplerenone; Male; Mesentery; Mice; Mice, Inbred C57BL; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Receptor, Angiotensin, Type 1; Spironolactone; Tetrazoles; Transglutaminases; Valine; Valsartan; Vasoconstriction; Vasodilation | 2008 |
Aldosterone induces mesangial cell apoptosis both in vivo and in vitro.
Topics: Aldosterone; Animals; Antioxidants; Apoptosis; bcl-Associated Death Protein; Blood Pressure; Creatinine; Cytochromes c; Eplerenone; Free Radical Scavengers; Humans; In Situ Nick-End Labeling; Kidney Glomerulus; Male; Mesangial Cells; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Proliferating Cell Nuclear Antigen; Rats; Rats, Sprague-Dawley; Spironolactone | 2008 |
Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Signaling; Cardiomyopathies; Cricetinae; Eplerenone; Heart Failure; Mineralocorticoid Receptor Antagonists; Models, Cardiovascular; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Renin-Angiotensin System; Spironolactone | 2008 |
Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder.
Topics: Aldosterone; Animals; Blood Pressure Determination; Disease Models, Animal; Echocardiography, Doppler; Eplerenone; Heart Failure, Diastolic; Heart Function Tests; Male; Metabolic Syndrome; Random Allocation; Rats; Rats, Inbred SHR; Reactive Oxygen Species; Reference Values; Sensitivity and Specificity; Sodium Chloride; Spironolactone; Urinalysis; Ventricular Dysfunction, Left | 2008 |
Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Animals, Newborn; Cells, Cultured; Down-Regulation; Eplerenone; Mineralocorticoid Receptor Antagonists; Myocytes, Cardiac; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Receptors, Mineralocorticoid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Time Factors | 2008 |
Aldosterone induces myofibroblastic transdifferentiation and collagen gene expression through the Rho-kinase dependent signaling pathway in rat mesangial cells.
Topics: Aldosterone; Amides; Animals; Cell Transdifferentiation; Collagen; Eplerenone; Gene Expression Regulation; Hypertrophy; Mesangial Cells; Mineralocorticoid Receptor Antagonists; Muscle Development; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; rho-Associated Kinases; Signal Transduction; Spironolactone | 2008 |
Effect of single treatment with the antihypertensive drug eplerenone on hormone levels and anxiety-like behaviour in rats.
Topics: Adrenocorticotropic Hormone; Aldosterone; Animals; Antihypertensive Agents; Anxiety; Behavior, Animal; Corticosterone; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Eplerenone; Hormones; Male; Maze Learning; Rats; Rats, Wistar; Renin; Spironolactone | 2008 |
Mechanisms in the PVN mediating local and central sodium-induced hypertension in Wistar rats.
Topics: Aldosterone; Amiloride; Angiotensins; Animals; Antihypertensive Agents; Blood Pressure; Cardiotonic Agents; Cerebrospinal Fluid; Diuretics; Dose-Response Relationship, Drug; Eplerenone; Heart Rate; Hypertension; Injections, Intraventricular; Losartan; Ouabain; Paraventricular Hypothalamic Nucleus; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Sodium; Spironolactone | 2009 |
Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms.
Topics: Aldosterone; Animals; Apoptosis; bcl-2-Associated X Protein; Cell Survival; Cells, Cultured; Drug Interactions; Eplerenone; Fenofibrate; Hypolipidemic Agents; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Signaling System; Mice; Mice, Inbred Strains; Mineralocorticoid Receptor Antagonists; Mitochondria; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocytes, Cardiac; p38 Mitogen-Activated Protein Kinases; PPAR alpha; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Spironolactone | 2009 |
Aldosterone in clinical nephrology--old hormone, new questions.
Topics: Aldosterone; Eplerenone; Humans; Hypertension; Kidney Diseases; Mineralocorticoid Receptor Antagonists; Nephrology; Spironolactone | 2009 |
Electrophysiological responses of sympathetic preganglionic neurons to ANG II and aldosterone.
Topics: Aldosterone; Anesthetics, Local; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Autonomic Fibers, Preganglionic; Benzimidazoles; Biphenyl Compounds; Eplerenone; Excitatory Postsynaptic Potentials; Female; In Vitro Techniques; Male; Mineralocorticoid Receptor Antagonists; Patch-Clamp Techniques; Presynaptic Terminals; Rats; Rats, Wistar; Spironolactone; Synaptic Transmission; Tetrazoles; Tetrodotoxin; Time Factors | 2009 |
Role of mineralocorticoid receptor on experimental cerebral aneurysms in rats.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Cerebral Arteries; Chemokine CCL2; Eplerenone; Female; Gene Expression; Hypertension, Renal; Immunohistochemistry; Intracranial Aneurysm; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; Ovariectomy; Oxidative Stress; Peptidyl-Dipeptidase A; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tyrosine | 2009 |
Update in primary aldosteronism.
Topics: Adrenalectomy; Adrenocorticotropic Hormone; Aldosterone; Amiloride; Antihypertensive Agents; Chromosomes, Human, Pair 7; Cytochrome P-450 CYP11B2; Diagnosis, Differential; Drug Administration Schedule; Eplerenone; Genetic Linkage; Glucocorticoids; Humans; Hyperaldosteronism; Hypertension; Lod Score; Mineralocorticoid Receptor Antagonists; Spironolactone | 2009 |
Eplerenone, a selective mineralocorticoid receptor blocker, exerts anxiolytic effects accompanied by changes in stress hormone release.
Topics: Adrenal Cortex; Aldosterone; Animals; Anti-Anxiety Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Corticosterone; Eplerenone; Exploratory Behavior; Hippocampus; Male; Mineralocorticoid Receptor Antagonists; Neuronal Plasticity; Oxytocin; Pituitary Gland, Posterior; Random Allocation; Rats; Rats, Wistar; Spironolactone; Stress, Psychological; Vasopressins | 2010 |
Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Asian People; Calcium Channel Blockers; Drug Therapy, Combination; Eplerenone; Female; Humans; Hypertension; Japan; Male; Metabolic Syndrome; Middle Aged; Mineralocorticoid Receptor Antagonists; Renin; Spironolactone; Treatment Outcome; Triglycerides | 2010 |
Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aldosterone; Animals; Blood Pressure; Eplerenone; Fibrosis; Heart; Immunohistochemistry; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Myocardium; Oxidative Stress; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; rho-Associated Kinases; Sodium Chloride; Spironolactone | 2010 |
Renoprotective effects of mineralocorticoid receptor blockade in heminephrectomized (pro)renin receptor transgenic rats.
Topics: Aldosterone; Animals; Eplerenone; Humans; Kidney Diseases; Mineralocorticoid Receptor Antagonists; Nephrectomy; Prorenin Receptor; Rats; Rats, Transgenic; Receptors, Cell Surface; Sodium Chloride, Dietary; Spironolactone | 2010 |
The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family.
Topics: Aldosterone; Binding Sites; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; Calcium Channels, T-Type; Cell Line; Dihydropyridines; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Models, Molecular; Molecular Conformation; Mutation; Pyridines; Receptors, Mineralocorticoid; Spironolactone; Stereoisomerism | 2010 |
Sensitivity of NOS-dependent vascular relaxation pathway to mineralocorticoid receptor blockade in caveolin-1-deficient mice.
Topics: Acetylcholine; Aldosterone; Animals; Caveolin 1; Eplerenone; Male; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Models, Animal; Muscle Relaxation; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Phenylephrine; Receptors, Mineralocorticoid; Signal Transduction; Sodium Chloride, Dietary; Spironolactone; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2010 |
Aldosterone receptor inhibition alters the viscoelastic biomechanical behavior of the aortic wall.
Topics: Aldosterone; Animals; Aorta; Biomechanical Phenomena; Blood Pressure; Disease Progression; Elasticity; Eplerenone; Hyperlipidemias; Male; Mineralocorticoid Receptor Antagonists; Rabbits; Spironolactone; Viscosity | 2010 |
Aldosterone and mineralocorticoid receptor antagonists modulate elastin and collagen deposition in human skin.
Topics: Adult; Aldosterone; Biopsy; Cells, Cultured; Cicatrix; Collagen Type I; Elasticity; Elastin; Eplerenone; Extracellular Matrix; Female; Fibroblasts; Gene Expression; Humans; Keloid; Mineralocorticoid Receptor Antagonists; Organ Culture Techniques; Receptor, IGF Type 1; RNA, Messenger; Skin; Spironolactone; Up-Regulation | 2010 |
Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats.
Topics: Albuminuria; Aldosterone; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Benzimidazoles; Benzoates; Blotting, Western; Calcium Channel Blockers; Eplerenone; Immunoenzyme Techniques; Kidney Glomerulus; Male; Membrane Proteins; Mineralocorticoid Receptor Antagonists; Podocytes; Proteinuria; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Telmisartan | 2011 |
Aldosterone and angiogenesis.
Topics: Aldosterone; Animals; Dogs; Eplerenone; Mineralocorticoid Receptor Antagonists; Neovascularization, Physiologic; Rats; Rats, Wistar; Spironolactone | 2010 |
Acid retention during kidney failure induces endothelin and aldosterone production which lead to progressive GFR decline, a situation ameliorated by alkali diet.
Topics: Acid-Base Equilibrium; Acidosis; Administration, Oral; Aldosterone; Animals; Bicarbonates; Calcium Gluconate; Dietary Supplements; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin-1; Eplerenone; Female; Glomerular Filtration Rate; Kidney; Male; Microdialysis; Mineralocorticoid Receptor Antagonists; Nephrectomy; Phenylpropionates; Pyrimidines; Rats; Rats, Wistar; Receptor, Endothelin A; Renal Insufficiency; Spironolactone; Time Factors | 2010 |
Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans.
Topics: Aldosterone; Animals; Cells, Cultured; Cyclic AMP-Dependent Protein Kinases; Endothelial Cells; Endothelium, Vascular; Eplerenone; Female; Humans; Hyperaldosteronism; Male; Mice; Middle Aged; Mineralocorticoid Receptor Antagonists; Reactive Oxygen Species; Receptors, Mineralocorticoid; Spironolactone; Stem Cells; Vasodilation | 2011 |
Aldosterone/Mineralocorticoid receptor stimulation induces cellular senescence in the kidney.
Topics: Acetylglucosaminidase; Aldosterone; Animals; Blood Pressure; Blotting, Western; Cells, Cultured; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Eplerenone; Humans; Hydralazine; Hypertension; Kidney; Male; Mineralocorticoid Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sirtuin 1; Spironolactone; Tumor Suppressor Protein p53 | 2011 |
Eplerenone suppresses aldosterone/ salt-induced expression of NOX-4.
Topics: Acetophenones; Aldosterone; Animals; Blood Pressure; Blotting, Western; Body Weight; Dinoprost; Eplerenone; Male; NADPH Oxidase 4; NADPH Oxidases; Nitric Oxide; Protein Subunits; Proteinuria; Rats; Rats, Inbred Dahl; Sodium; Sodium Chloride, Dietary; Spironolactone; Systole; Urinalysis | 2011 |
Eplerenone in mild heart failure.
Topics: Aldosterone; Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Sodium, Dietary; Spironolactone; Stroke Volume | 2011 |
Angiotensin II and aldosterone-induced neuronal damage in neurons through an astrocyte-dependent mechanism.
Topics: Aldosterone; Angiotensin II; Animals; Astrocytes; Cells, Cultured; DNA Damage; Eplerenone; Ganglia, Spinal; Mice; Mice, Inbred C57BL; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Spironolactone; Tetrazoles; Valine; Valsartan | 2011 |
Eplerenone potentiates protective effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats.
Topics: Aldosterone; Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Carotid Arteries; Drug Therapy, Combination; Endothelium, Vascular; Eplerenone; Heart; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Nitric Oxide Synthase Type III; Oxidative Stress; Proto-Oncogene Proteins c-akt; Rats; Rats, Inbred Dahl; Receptor, Angiotensin, Type 1; Sodium Chloride, Dietary; Spironolactone; Superoxides; Treatment Outcome | 2011 |
Mineralocorticoid receptor activation: a major contributor to salt-induced renal injury and hypertension in young rats.
Topics: Acute Kidney Injury; Aldosterone; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Eplerenone; Hypertension; Imidazoles; Immunohistochemistry; Kidney; Male; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Reverse Transcriptase Polymerase Chain Reaction; Sodium Chloride; Spironolactone; Tetrazoles | 2011 |
[The EMPHASIS-HF study].
Topics: Aldosterone; Biomarkers; Canrenone; Cause of Death; Double-Blind Method; Early Termination of Clinical Trials; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; Male; Mineralocorticoid Receptor Antagonists; Models, Cardiovascular; Molecular Structure; Multicenter Studies as Topic; Myocardial Infarction; Patient Selection; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Research Design; Risk; Spironolactone | 2011 |
Effects of aldosterone and related steroids on LPS-induced increased expression of inducible NOS in rat aortic smooth muscle cells.
Topics: Aldosterone; Animals; Aorta, Thoracic; Cells, Cultured; Eplerenone; Lipopolysaccharides; Male; Mifepristone; Muscle, Smooth, Vascular; Nitric Oxide Synthase Type II; Rats; Rats, Sprague-Dawley; Spironolactone; Steroids | 2011 |
Glucocorticoid and mineralocorticoid receptors regulate paracellular permeability in a primary cultured gill epithelium.
Topics: Aldosterone; Animals; Cell Membrane Permeability; Cells, Cultured; Desoxycorticosterone; Dexamethasone; Electric Impedance; Epithelial Cells; Epithelium; Eplerenone; Fish Proteins; Gene Expression Regulation; Gills; Hydrocortisone; Mifepristone; Mineralocorticoid Receptor Antagonists; Oncorhynchus mykiss; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tight Junctions | 2011 |
Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney.
Topics: Albuminuria; Aldosterone; Animals; Blood Pressure; Eplerenone; Fibrosis; Inflammation; Kidney; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Osteopontin; Oxidative Stress; Sodium Chloride, Dietary; Spironolactone | 2011 |
Adipocyte-derived factors regulate vascular smooth muscle cells through mineralocorticoid and glucocorticoid receptors.
Topics: 3T3-L1 Cells; Adipocytes; Aldosterone; Angiotensin II; Animals; Blotting, Western; Cells, Cultured; Corticosterone; Culture Media, Conditioned; Eplerenone; Fadrozole; Fibronectins; Hormone Antagonists; Mice; Mice, Inbred C57BL; Mifepristone; Mineralocorticoid Receptor Antagonists; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-bcl-2; Receptor, Angiotensin, Type 1; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Spironolactone | 2011 |
Delineating the receptor mechanisms underlying the rapid vascular contractile effects of aldosterone and estradiol.
Topics: Aldosterone; Animals; Cells, Cultured; Eplerenone; Estradiol; Estrogen Receptor alpha; Muscle Contraction; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Myosin Light Chains; Phosphorylation; Rats; Rats, Inbred WKY; Receptors, G-Protein-Coupled; Receptors, Mineralocorticoid; Signal Transduction; Spironolactone; Tamoxifen; Vasoconstriction | 2011 |
The effect of treatment on monocyte and lymphocyte cytokine release in patients with aldosteronoma.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Adenoma; Adult; Aldosterone; Blood Pressure; Cytokines; Eplerenone; Female; Humans; Lymphocytes; Mineralocorticoid Receptor Antagonists; Monocytes; Spironolactone | 2012 |
Chronic antagonism of the mineralocorticoid receptor ameliorates hypertension and end organ damage in a rodent model of salt-sensitive hypertension.
Topics: Aldosterone; Animals; Blood Pressure; Chronic Disease; Creatinine; Disease Models, Animal; Disease Progression; Electrolytes; Eplerenone; Heart Rate; Hypertension, Renal; Kidney; Male; Mineralocorticoid Receptor Antagonists; Organ Size; Rats; Rats, Inbred Dahl; Receptors, Mineralocorticoid; Sodium Chloride, Dietary; Spironolactone | 2011 |
What is the role of aldosterone excess in resistant hypertension and how should it be investigated and treated?
Topics: Aldosterone; Eplerenone; Female; Humans; Hyperaldosteronism; Hyperkalemia; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Spironolactone | 2011 |
Mineralocorticoid receptor antagonists for heart failure.
Topics: Aldosterone; Animals; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2011 |
Aldosterone does not contribute to renal p21 expression during the development of angiotensin II-induced hypertension in mice.
Topics: Actins; Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cellular Senescence; Eplerenone; Genes, p16; Genes, p53; Hydralazine; Hypertension; Imidazoles; Kidney; Mice; Mice, Inbred C57BL; p21-Activated Kinases; Sirtuin 1; Sodium Chloride; Spironolactone; Tetrazoles | 2012 |
Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor.
Topics: Aldosterone; Animals; Aorta, Thoracic; Blood Pressure; Cells, Cultured; Chimera; Eplerenone; Glucose; Hypertrophy; Insulin; Insulin Resistance; Male; Models, Animal; Muscle, Smooth, Vascular; Oxidative Stress; Rats; Rats, Sprague-Dawley; Receptor, IGF Type 1; Receptor, Insulin; Spironolactone; Up-Regulation | 2012 |
Aldosterone inhibits endothelial morphogenesis and angiogenesis through the downregulation of vascular endothelial growth factor receptor-2 expression subsequent to peroxisome proliferator-activated receptor gamma.
Topics: Aldosterone; Angiogenesis Inhibitors; Animals; Collagen; Down-Regulation; Drug Combinations; Endothelium; Eplerenone; Human Umbilical Vein Endothelial Cells; Humans; Laminin; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Morphogenesis; Neovascularization, Physiologic; PPAR gamma; Proteoglycans; Spironolactone; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Activation of mineralocorticoid receptors in the rostral ventrolateral medulla is involved in hypertensive mechanisms in stroke-prone spontaneously hypertensive rats.
Topics: Aldosterone; Animals; Blood Pressure; Eplerenone; Hypertension; Male; Medulla Oblongata; Microinjections; Mineralocorticoid Receptor Antagonists; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Mineralocorticoid; Spironolactone; Stroke; Sympathetic Nervous System | 2012 |
Antiapolipoprotein A-1 IgG chronotropic effects require nongenomic action of aldosterone on L-type calcium channels.
Topics: Aldosterone; Animals; Animals, Newborn; Apolipoprotein A-I; Calcium Channels, L-Type; Cells, Cultured; Dactinomycin; Electrophysiology; Eplerenone; Immunoglobulin G; Myocytes, Cardiac; Oxidation-Reduction; Oxygen; Phosphatidylinositol 3-Kinases; Rats; Rats, Wistar; Receptors, Mineralocorticoid; Spironolactone; Time Factors | 2012 |
Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients.
Topics: Adipocytes; Adiponectin; Adult; Aged; Aldosterone; Carrier Proteins; Cells, Cultured; Down-Regulation; Eplerenone; Female; Gene Expression; Humans; Hyperaldosteronism; Insulin Resistance; Intra-Abdominal Fat; Intracellular Signaling Peptides and Proteins; Lipid Metabolism; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Perilipin-1; Phosphoenolpyruvate Carboxykinase (GTP); Phosphoproteins; Potassium; PPAR gamma; Spironolactone | 2012 |
Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation.
Topics: Acute Kidney Injury; Adrenalectomy; Aldosterone; Analysis of Variance; Angiotensin II; Animals; Blotting, Western; Disease Models, Animal; Eplerenone; Immunohistochemistry; Male; Mice; Mice, Inbred Strains; rac1 GTP-Binding Protein; Random Allocation; Real-Time Polymerase Chain Reaction; Receptors, Mineralocorticoid; Signal Transduction; Sodium Chloride, Dietary; Spironolactone; Statistics, Nonparametric | 2012 |
Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Eplerenone; Heart; Heart Failure; Hospitalization; Humans; Kidney; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Randomized Controlled Trials as Topic; Spironolactone; Stroke Volume; Ventricular Dysfunction, Left | 2012 |
Aldosterone inhibits antifibrotic factors in mouse hypertensive heart.
Topics: Aldosterone; Animals; Animals, Newborn; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Blood Pressure; Blotting, Western; Bone Morphogenetic Protein 4; Cells, Cultured; Cytochrome P-450 CYP11B2; Eplerenone; Female; Fibrosis; Galectin 3; Gene Expression; Hyperaldosteronism; Hypertension; Male; Mice; Mice, Transgenic; Mineralocorticoid Receptor Antagonists; Myocardium; Natriuretic Peptide, Brain; Organ Size; Renin; Reverse Transcriptase Polymerase Chain Reaction; Spironolactone | 2012 |
Eplerenone inhibits aldosterone-induced renal expression of cyclooxygenase.
Topics: Acetophenones; Aldosterone; Animals; Blood Pressure; Blotting, Western; Cyclooxygenase 1; Cyclooxygenase 2; Dinoprostone; Eplerenone; Epoprostenol; Heart Rate; Immunohistochemistry; Kidney; Male; Membrane Proteins; Rats; Rats, Inbred Dahl; Spironolactone; Systole; Vasoconstrictor Agents | 2012 |
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Rats; Receptors, Mineralocorticoid; Retina; Signal Transduction; Small-Conductance Calcium-Activated Potassium Channels; Spironolactone; Treatment Outcome; Vasodilation; Vasodilator Agents; Visual Acuity | 2012 |
Mineralocorticoid receptor blockade inhibits accelerated atherosclerosis induced by a low sodium diet in apolipoprotein E-deficient mice.
Topics: Aldosterone; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Biomarkers; Diet, Sodium-Restricted; Eplerenone; Humans; Inflammation; Macrophages, Peritoneal; Mice; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Renin; Renin-Angiotensin System; Spironolactone | 2014 |
Aldosterone-specific activation of cardiomyocyte mineralocorticoid receptor in vivo.
Topics: Aldosterone; Animals; Connective Tissue Growth Factor; Eplerenone; Mice; Mice, Transgenic; Mineralocorticoid Receptor Antagonists; Myocytes, Cardiac; Receptors, Mineralocorticoid; Spironolactone; Transcriptome | 2013 |
Aldosterone is synthesized in and activates bulbospinal neurons through mineralocorticoid receptors and ENaCs in the RVLM.
Topics: Aldosterone; Amiloride; Animals; Aromatase Inhibitors; Calcium; Diuretics; Epithelial Sodium Channels; Eplerenone; Excitatory Postsynaptic Potentials; Fadrozole; Magnesium; Medulla Oblongata; Membrane Potentials; Neurons; Patch-Clamp Techniques; Rats; Rats, Wistar; Receptors, Mineralocorticoid; Spinal Cord; Spironolactone; Tissue Fixation | 2013 |
Rho kinase pathway is likely responsible for the profibrotic actions of aldosterone in renal epithelial cells via inducing epithelial-mesenchymal transition and extracellular matrix excretion.
Topics: Actins; Aldosterone; Amides; Cadherins; Cell Line; Collagen Type I; Collagen Type III; Epithelial Cells; Epithelial-Mesenchymal Transition; Eplerenone; Extracellular Matrix; Gene Expression Regulation; Humans; Kidney; Mineralocorticoid Receptor Antagonists; Protein Kinase Inhibitors; Pyridines; Receptors, Mineralocorticoid; rho-Associated Kinases; RNA, Messenger; Signal Transduction; Spironolactone | 2013 |
Blood pressure variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in hypertensive rats.
Topics: Active Transport, Cell Nucleus; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Cell Nucleus; Eplerenone; Humans; Hydrocortisone; Hypertension; Macrophages; Mineralocorticoid Receptor Antagonists; Muscle Proteins; Myocarditis; Myocardium; p21-Activated Kinases; Phosphorylation; Rats; Rats, Inbred SHR; Receptors, Mineralocorticoid; Spironolactone; Ventricular Remodeling | 2013 |
The effects of aldosterone on diet-induced fatty liver formation in male C57BL/6 mice: comparison of adrenalectomy and mineralocorticoid receptor blocker.
Topics: Adrenalectomy; Aldosterone; Animals; Blood Glucose; Blood Pressure; Cells, Cultured; Cholesterol; Diet, High-Fat; Disease Models, Animal; Eplerenone; Fatty Liver; Hepatocytes; Insulin; Insulin Resistance; Lipoproteins, VLDL; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Oleic Acid; Spironolactone; Triglycerides; Weight Gain | 2013 |
Eplerenone promotes alternative activation in human monocyte-derived macrophages.
Topics: Adolescent; Adult; Aldosterone; Arginase; Cells, Cultured; Eplerenone; Female; Gene Expression Regulation; Humans; Lectins, C-Type; Macrophages; Male; Mannose Receptor; Mannose-Binding Lectins; Mineralocorticoid Receptor Antagonists; Nitric Oxide; Nitric Oxide Synthase Type II; Reactive Oxygen Species; Receptors, Cell Surface; Spironolactone; Young Adult | 2013 |
Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity.
Topics: Adipose Tissue; Aldosterone; Animals; Antioxidants; Aorta; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Cytochrome P-450 Enzyme System; Diet, High-Fat; Endothelium, Vascular; Eplerenone; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Hyperglycemia; Inflammation; Intramolecular Oxidoreductases; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Obesity; Oxidative Stress; Receptors, Mineralocorticoid; Spironolactone; Superoxide Dismutase; Superoxide Dismutase-1; Up-Regulation | 2013 |
Renin angiotensin antagonists normalize aberrant activation of epithelial sodium channels in sodium-sensitive hypertension.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Down-Regulation; Epithelial Sodium Channels; Eplerenone; Hypertension; Imidazoles; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Perindopril; Renin; Sodium; Sodium Chloride, Dietary; Spironolactone; Tetrazoles | 2012 |
Mineralocorticoid receptor agonists induce mouse aortic aneurysm formation and rupture in the presence of high salt.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Aortic Aneurysm, Abdominal; Aortic Aneurysm, Thoracic; Aortic Rupture; Apoptosis; Blood Pressure; Desoxycorticosterone; Disease Models, Animal; Elastin; Enalapril; Eplerenone; Losartan; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Oxidative Stress; Receptors, Mineralocorticoid; Sodium Chloride, Dietary; Spironolactone; Time Factors | 2013 |
Echocardiographic effects of eplerenone and aldosterone in hypertensive rats.
Topics: Aldosterone; Animals; Echocardiography; Eplerenone; Hypertension; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Spironolactone | 2013 |
Aldosterone signaling through transient receptor potential melastatin 7 cation channel (TRPM7) and its α-kinase domain.
Topics: Adenosine Triphosphate; Aldosterone; Annexin A1; Binding Sites; Boron Compounds; Calpain; Eplerenone; Gene Expression Regulation; HEK293 Cells; Humans; Ion Transport; Magnesium; NADPH Oxidases; Phosphorylation; Protein Binding; Protein Kinases; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Reactive Oxygen Species; Signal Transduction; Spectrin; Spironolactone; TRPM Cation Channels | 2013 |
Role of brain corticosterone and aldosterone in central angiotensin II-induced hypertension.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Brain; Corticosterone; Cytochrome P-450 CYP11B2; Dose-Response Relationship, Drug; Eplerenone; Fadrozole; Heart Rate; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Spironolactone | 2013 |
Anatomical location and redistribution of G protein-coupled estrogen receptor-1 during the estrus cycle in mouse kidney and specific binding to estrogens but not aldosterone.
Topics: Aldosterone; Animals; Eplerenone; Estradiol; Estrus; Female; Gene Expression Regulation; Guanosine 5'-O-(3-Thiotriphosphate); HEK293 Cells; Humans; Kidney Tubules, Distal; Loop of Henle; Low Density Lipoprotein Receptor-Related Protein-2; Mice; Mineralocorticoid Receptor Antagonists; Protein Binding; Receptors, Estrogen; Receptors, G-Protein-Coupled; Receptors, Mineralocorticoid; Reproduction; Spironolactone | 2014 |
Eplerenone mimics features of the alternative activation in macrophages obtained from patients with heart failure and healthy volunteers.
Topics: Aged; Aldosterone; Arginase; Cell Survival; Drug Interactions; Eplerenone; Female; Gene Expression Regulation; Healthy Volunteers; Heart Failure; Humans; Interleukin-4; Lectins, C-Type; Macrophage Activation; Macrophages; Male; Mannose Receptor; Mannose-Binding Lectins; Middle Aged; Mineralocorticoid Receptor Antagonists; Nitric Oxide; Nitric Oxide Synthase Type II; Phenotype; Reactive Oxygen Species; Receptors, Cell Surface; Receptors, Mineralocorticoid; Spironolactone; Superoxide Dismutase | 2014 |
The velocity of home blood pressure reduction in response to low-dose eplerenone combined with other antihypertensive drugs determined by exponential decay function analysis.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Drug Therapy, Combination; Eplerenone; Female; Humans; Hypertension; Male; Middle Aged; Spironolactone; Treatment Outcome | 2014 |
Preconditioning actions of aldosterone through p38 signaling modulation in isolated rat hearts.
Topics: Aldosterone; Animals; Eplerenone; Heart; Ischemic Preconditioning, Myocardial; Male; Myocardial Reperfusion Injury; Myocardium; p38 Mitogen-Activated Protein Kinases; Perfusion; Rats; Rats, Wistar; Signal Transduction; Spironolactone | 2014 |
Aldosterone sensitizes connecting tubule glomerular feedback via the aldosterone receptor GPR30.
Topics: Aldosterone; Amiloride; Animals; Arterioles; Cycloheximide; Dactinomycin; Epithelial Sodium Channels; Eplerenone; Feedback; Kidney Tubules; Male; Rabbits; Receptors, G-Protein-Coupled; Receptors, Mineralocorticoid; Spironolactone | 2014 |
Cardiac macrophages and apoptosis after myocardial infarction: effects of central MR blockade.
Topics: Aldosterone; Animals; Apoptosis; Caspase 3; Disease Models, Animal; Eplerenone; Macrophages; Male; Myocardial Infarction; Rats, Wistar; Receptors, Mineralocorticoid; Spironolactone; Ventricular Remodeling | 2014 |
Non-genomic effects of spironolactone and eplerenone in cardiomyocytes of neonatal Wistar rats: do they evoke cardioprotective pathways?
Topics: Aldosterone; Animals; Calcium; Cell Proliferation; Cyclic AMP; Cyclic GMP; Eplerenone; Female; Male; MAP Kinase Signaling System; Mineralocorticoid Receptor Antagonists; Myocytes, Cardiac; Protein Kinase C; Rats; Rats, Wistar; Signal Transduction; Spironolactone | 2015 |
Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity.
Topics: Adrenalectomy; Aldosterone; Animals; Chronic Disease; Cyclosporine; Cytochrome P-450 CYP11B2; Disease Models, Animal; Electrolytes; Eplerenone; Fibrosis; Kidney; Kidney Diseases; Male; Potassium; Rats, Sprague-Dawley; RNA, Messenger; Sodium; Spironolactone | 2015 |
Oxidative DNA damage in kidneys and heart of hypertensive mice is prevented by blocking angiotensin II and aldosterone receptors.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cyclic N-Oxides; Deoxyguanosine; DNA Damage; DNA Repair; Enzyme Activation; Eplerenone; Guanosine; Heart; Hypertension; Kidney; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; NF-E2-Related Factor 2; NF-kappa B; Oxidative Stress; Reactive Oxygen Species; Renin-Angiotensin System; Spin Labels; Spironolactone; Tetrazoles | 2014 |
Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
Topics: Administration, Oral; Adrenalectomy; Aldosterone; Animals; Antihypertensive Agents; Binding, Competitive; Blood Pressure; Desoxycorticosterone Acetate; Disease Models, Animal; Dose-Response Relationship, Drug; Eplerenone; Female; HEK293 Cells; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Potassium; Protein Binding; Pyrroles; Rabbits; Radioligand Assay; Rats, Inbred WKY; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Sodium; Spironolactone; Sulfones; Transcriptional Activation; Transfection; Urological Agents; Water-Electrolyte Balance | 2015 |
Role of brain aldosterone and mineralocorticoid receptors in aldosterone-salt hypertension in rats.
Topics: Aldosterone; Animals; Arterial Pressure; Corticosterone; Cytochrome P-450 CYP11B2; Drinking Behavior; Eplerenone; Fadrozole; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Neurons; Paraventricular Hypothalamic Nucleus; Rats; Rats, Wistar; Receptors, Mineralocorticoid; RNA, Messenger; Sodium Chloride; Spironolactone; Subfornical Organ; Supraoptic Nucleus | 2016 |
Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism.
Topics: Adrenalectomy; Adult; Aged; Aldosterone; Atherosclerosis; Biomarkers; Carotid Intima-Media Thickness; Drug Monitoring; Eplerenone; Female; Follow-Up Studies; Humans; Hyperaldosteronism; Hypertension; Hypokalemia; Japan; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Potassium; Reproducibility of Results; Risk; Spironolactone | 2016 |
Ceramide Production Mediates Aldosterone-Induced Human Umbilical Vein Endothelial Cell (HUVEC) Damages.
Topics: Aldosterone; Ceramides; Eplerenone; Gene Knockdown Techniques; Human Umbilical Vein Endothelial Cells; Humans; Lysophospholipids; Membrane Proteins; Signal Transduction; Sphingosine; Sphingosine N-Acyltransferase; Spironolactone | 2016 |
Hyperaldosteronism after decreased renal K+ excretion in KCNMB2 knockout mice.
Topics: Aldosterone; Animals; Blood Pressure; Epithelial Sodium Channels; Eplerenone; Female; Hyperaldosteronism; Kidney; Large-Conductance Calcium-Activated Potassium Channel beta Subunits; Male; Mice, Inbred C57BL; Mice, Knockout; Polyuria; Potassium; Sodium, Dietary; Solute Carrier Family 12, Member 3; Spironolactone | 2016 |
Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerenone in primary hyperparathyroidism trial.
Topics: Aged; Aldosterone; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium; Circadian Rhythm; Cross-Sectional Studies; Diastole; Eplerenone; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Primary; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Parathyroid Hormone; Randomized Controlled Trials as Topic; Renin; Risk Factors; Sex Factors; Spironolactone; Systole | 2016 |
ARAs to the RESCUE.
Topics: Aldosterone; Eplerenone; Gynecomastia; Humans; Hyperaldosteronism; Hypertension; Hypokalemia; Meta-Analysis as Topic; Mineralocorticoid Receptor Antagonists; Spironolactone | 2016 |
Aldosterone Upregulates Transient Receptor Potential Melastatin 7 (TRPM7).
Topics: Aldosterone; Benzoates; Bridged Bicyclo Compounds, Heterocyclic; Eplerenone; HEK293 Cells; Humans; Immediate-Early Proteins; Protein Domains; Protein Serine-Threonine Kinases; Receptors, Mineralocorticoid; Signal Transduction; Spironolactone; TRPM Cation Channels; Up-Regulation | 2016 |
Mineralocorticoid Receptor Blockade Improves Insulin Sensitivity in the Rat Heart and a Possible Molecular Mechanism.
Topics: Adiponectin; Aldosterone; Animals; Animals, Newborn; Biological Transport; Eplerenone; Gene Expression Regulation; Glucose; Glucose Clamp Technique; Insulin; Insulin Resistance; Male; Mineralocorticoid Receptor Antagonists; Myocytes, Cardiac; p38 Mitogen-Activated Protein Kinases; PPAR alpha; Primary Cell Culture; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; RNA, Messenger; Signal Transduction; Spironolactone | 2016 |
Aldosterone Synthase Inhibition Improves Glucose Tolerance in Zucker Diabetic Fatty (ZDF) Rats.
Topics: Adrenal Glands; Aldosterone; Animals; Blood Glucose; Body Weight; Cytochrome P-450 CYP11B2; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Evaluation, Preclinical; Eating; Eplerenone; Fadrozole; Glucose Tolerance Test; Glycated Hemoglobin; Insulin; Insulin Resistance; Insulin Secretion; Liver; Male; Mineralocorticoid Receptor Antagonists; Organ Size; Potassium; Random Allocation; Rats, Zucker; Sodium; Spironolactone; Triglycerides | 2016 |
The Clinical Value of Salivary Aldosterone in Diagnosis and Follow-Up of Primary Aldosteronism.
Topics: Adrenalectomy; Aged; Aldosterone; Case-Control Studies; Circadian Rhythm; Eplerenone; Female; Follow-Up Studies; Humans; Hyperaldosteronism; Hypertension; Male; Middle Aged; Prognosis; Prospective Studies; Retrospective Studies; Saliva; Spironolactone | 2016 |
Caveolin 1 Modulates Aldosterone-Mediated Pathways of Glucose and Lipid Homeostasis.
Topics: Adipose Tissue; Adolescent; Adult; Aged; Aldehyde Reductase; Aldosterone; Animals; Blood Glucose; Caveolin 1; Cholesterol; Dyslipidemias; Eplerenone; Female; Gene Frequency; Glucose; Homeostasis; Humans; Hypertriglyceridemia; Insulin; Insulin Resistance; Lipid Metabolism; Lipoproteins, HDL; Liver; Male; Mice; Mice, Knockout; Middle Aged; Mineralocorticoid Receptor Antagonists; NADPH Oxidase 4; Polymorphism, Single Nucleotide; Receptors, Mineralocorticoid; Resistin; Retinol-Binding Proteins, Plasma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Spironolactone; Triglycerides; Young Adult | 2016 |
Pathophysiological aldosterone levels modify the secretory activity of cardiac progenitor cells.
Topics: Aldosterone; Animals; Cell Movement; Cell Proliferation; Cytokines; Eplerenone; Mice; Mineralocorticoid Receptor Antagonists; Myocardium; Proteome; Reproducibility of Results; Spironolactone; Stem Cells | 2017 |
The Inhibitory Effect of Eplerenone on Cell Proliferation in the Contralateral Kidneys of Rats with Unilateral Ureteral Obstruction.
Topics: Actins; Aldosterone; Animals; Cell Proliferation; Collagen; Eplerenone; Fibrosis; Immediate-Early Proteins; Kidney; Male; MAP Kinase Signaling System; Mineralocorticoid Receptor Antagonists; Proliferating Cell Nuclear Antigen; Protein Serine-Threonine Kinases; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Spironolactone; Tumor Necrosis Factor-alpha; Up-Regulation; Ureteral Obstruction | 2017 |
Gene expression effects of glucocorticoid and mineralocorticoid receptor agonists and antagonists on normal human skeletal muscle.
Topics: Adolescent; Adult; Aldosterone; Blotting, Western; Cells, Cultured; Eplerenone; Humans; Male; Muscle, Skeletal; Muscular Dystrophy, Duchenne; Prednisolone; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Spironolactone; Young Adult | 2017 |
A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy.
Topics: Albuminuria; Aldosterone; Animals; Blood Pressure; Eplerenone; Losartan; Mineralocorticoid Receptor Antagonists; Nephrectomy; Rats, Wistar; Renal Insufficiency, Chronic; Renin; Treatment Outcome | 2017 |
Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiotoxicity; Connective Tissue Growth Factor; Disease Models, Animal; Doxorubicin; Enalapril; Eplerenone; Male; Mice, Inbred C57BL; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Myocytes, Cardiac; Phosphatidylinositol 3-Kinase; Primary Prevention; Proto-Oncogene Proteins c-akt; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Renin-Angiotensin System; Signal Transduction; TOR Serine-Threonine Kinases; Ventricular Dysfunction, Left; Ventricular Function, Left | 2018 |
Mineralocorticoid receptor antagonism protects the aorta from vascular smooth muscle cell proliferation and collagen deposition in a rat model of adrenal aldosterone-producing adenoma.
Topics: ACTH-Secreting Pituitary Adenoma; Aldosterone; Animals; Antihypertensive Agents; Aorta; Cell Proliferation; Collagen; Disease Models, Animal; Eplerenone; Hydralazine; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Proto-Oncogene Proteins c-mdm2; Random Allocation; Rats, Sprague-Dawley; Spironolactone; Transforming Growth Factor beta; Vascular Remodeling; Vasodilator Agents | 2018 |
Aldosterone is involved in the pathogenesis of obesity-related glomerulopathy through activation of Wnt/β-catenin signaling in podocytes.
Topics: Aldosterone; Animals; beta Catenin; Disease Models, Animal; Down-Regulation; Eplerenone; Glomerulonephritis; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Kidney Cortex; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Obesity; Podocytes; Sialoglycoproteins; Spironolactone; Wnt Proteins; Wnt Signaling Pathway | 2018 |
Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion.
Topics: Administration, Oral; Aldosterone; Animals; Benzoates; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Eplerenone; Humans; Kidney; Male; Mice, Mutant Strains; Mineralocorticoid Receptor Antagonists; Molecular Structure; Oxazines; Potassium; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Renal Insufficiency, Chronic; Sodium; Sodium, Dietary; Spironolactone | 2018 |
Elevated FGF23 Levels in Mice Lacking the Thiazide-Sensitive NaCl cotransporter (NCC).
Topics: Aldosterone; Analysis of Variance; Animals; Calcium; Disease Models, Animal; Eplerenone; Femur; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Gitelman Syndrome; Glucuronidase; Hydrochlorothiazide; Hypovolemia; Klotho Proteins; Male; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Parathyroid Hormone; Phosphates; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Drug; Sodium Chloride Symporters; Thiazides | 2018 |
Eplerenone improves endothelial function and arterial stiffness and inhibits Rho-associated kinase activity in patients with idiopathic hyperaldosteronism: a pilot study.
Topics: Adult; Aldosterone; Ankle Brachial Index; Antihypertensive Agents; Blood Pressure; Brachial Artery; Endothelium, Vascular; Eplerenone; Female; Humans; Hyperaldosteronism; Hyperemia; Hypertension; Male; Microvessels; Middle Aged; Nitroglycerin; Pilot Projects; Pulse Wave Analysis; Renin; rho-Associated Kinases; Ultrasonography; Vascular Stiffness; Vasodilation; Vasodilator Agents | 2019 |
Aldosterone Modulates the Mechanistic Target of Rapamycin Signaling in Male Mice.
Topics: Aldosterone; Animals; Eplerenone; Heart; Kidney; Male; Mice; Myocardium; Phosphorylation; Signal Transduction; TOR Serine-Threonine Kinases | 2019 |
Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.
Topics: Aldosterone; Animals; Anti-Inflammatory Agents; Cardiomyopathies; Computer Simulation; CRISPR-Associated Protein 9; Disease Models, Animal; Eplerenone; Gene Knockout Techniques; Hydrogen Bonding; Macrophages; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Muscular Dystrophy, Duchenne; Myocarditis; Myocytes, Cardiac; Prednisolone; Pregnadienediols; RAW 264.7 Cells; Receptors, Glucocorticoid; Receptors, Mineralocorticoid | 2019 |
Mineralocorticoid Receptor Antagonists Stimulate Human Hair Growth ex vivo.
Topics: Adult; Aged; Aldosterone; Eplerenone; Female; Hair; Humans; Middle Aged; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Spironolactone | 2019 |
The effect of eplerenone on the renin-angiotensin-aldosterone system of rats with thyroid dysfunction.
Topics: Aldosterone; Angiotensin I; Animals; Antihypertensive Agents; Eplerenone; Hyperthyroidism; Hypothyroidism; Male; Rats; Rats, Wistar; Renin; Renin-Angiotensin System | 2019 |
Lysine-Specific Demethylase-1 Deficiency Increases Agonist Signaling Via the Mineralocorticoid Receptor.
Topics: Aldosterone; Alleles; Animals; Blood Pressure; Epigenesis, Genetic; Eplerenone; Histone Demethylases; Kidney; Male; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Mutation; Potassium; Receptors, Mineralocorticoid; Signal Transduction | 2020 |
Striatin heterozygous mice are more sensitive to aldosterone-induced injury.
Topics: Aldosterone; Animals; Blood Pressure; Calmodulin-Binding Proteins; Eplerenone; Kidney; Male; Membrane Proteins; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Nerve Tissue Proteins; NG-Nitroarginine Methyl Ester; Pyrroles; Spironolactone; Sulfones | 2020 |
Mineralocorticoid Receptor Antagonists in ESKD.
Topics: Aldosterone; Cardiovascular Diseases; Eplerenone; Humans; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Spironolactone | 2020 |
Impact of mineralocorticoid receptor blockade with direct renin inhibition in angiotensin II-dependent hypertensive mice.
Topics: Aldosterone; Amides; Animals; Antihypertensive Agents; Drug Evaluation, Preclinical; Drug Therapy, Combination; Eplerenone; Fumarates; Hypertension; Male; Mice; Mineralocorticoid Receptor Antagonists | 2020 |
A Comparison of Adrenalectomy and Eplerenone on Vascular Function in Patients with Aldosterone-producing Adenoma.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Adenoma; Adult; Aldosterone; Blood Pressure; Endothelium, Vascular; Eplerenone; Female; Humans; Hyperaldosteronism; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Nitroglycerin; Vasodilation | 2020 |
Aldosterone and dexamethasone activate African lungfish mineralocorticoid receptor: Increased activation after removal of the amino-terminal domain.
Topics: Aldosterone; Animals; Corticosterone; Cortodoxone; Desoxycorticosterone; Dexamethasone; Eplerenone; Fish Proteins; Fishes; Gene Expression; Hydrocortisone; Kinetics; Progesterone; Protein Domains; Protein Engineering; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Recombinant Proteins; Spironolactone; Triamcinolone | 2022 |
Biglycan Is a Novel Mineralocorticoid Receptor Target Involved in Aldosterone/Salt-Induced Glomerular Injury.
Topics: Aldosterone; Animals; Biglycan; Eplerenone; Kidney Diseases; Mice; Mineralocorticoid Receptor Antagonists; NF-kappa B; Receptors, Mineralocorticoid; Signal Transduction; Sodium Chloride, Dietary; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2022 |
Aldosterone Increases Vascular Permeability in Rat Skin.
Topics: Aldosterone; Animals; Capillary Permeability; Eplerenone; Mineralocorticoid Receptor Antagonists; Rats; Vascular Endothelial Growth Factor A; von Willebrand Factor | 2022 |
Esaxerenone inhibits the macrophage-to-myofibroblast transition through mineralocorticoid receptor/TGF-β1 pathway in mice induced with aldosterone.
Topics: Aldosterone; Animals; Eplerenone; Fibrosis; Macrophages; Mice; Myofibroblasts; Pyrroles; Rats; Receptors, Mineralocorticoid; Renal Insufficiency, Chronic; Sulfones; Transforming Growth Factor beta1 | 2022 |
Eplerenone Prevents Cardiac Fibrosis by Inhibiting Angiogenesis in Unilateral Urinary Obstruction Rats.
Topics: Actins; Aldosterone; Animals; Collagen; Eosine Yellowish-(YS); Eplerenone; Fibrosis; Glucocorticoids; Hematoxylin; Interleukin-1beta; Kidney; NF-kappa B; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Renal Insufficiency, Chronic; RNA, Messenger; Ureteral Obstruction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Ventricular Remodeling | 2022 |
[New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects].
Topics: Aldosterone; COVID-19 Drug Treatment; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; SARS-CoV-2; Spironolactone | 2021 |
Eplerenone inhibits the macrophage-to-myofibroblast transition in rats with UUO-induced type 4 cardiorenal syndrome through the MR/CTGF pathway.
Topics: Aldosterone; Animals; Cardio-Renal Syndrome; Eplerenone; Fibrosis; Heart Diseases; Macrophages; Myofibroblasts; Rats; Receptors, Mineralocorticoid; Renal Insufficiency, Chronic | 2022 |
Differential Role of Aldosterone and Transforming Growth Factor Beta-1 in Cardiac Remodeling.
Topics: Aldosterone; Animals; Cardiomegaly; Eplerenone; Fibrosis; Male; Mice; Mice, Transgenic; Myocytes, Cardiac; Transforming Growth Factor beta1; Ventricular Remodeling | 2023 |
Unilateral adrenalectomy for a drug-resistant bilateral primary aldosteronism with heart failure: pathophysiology and surgical indication.
Topics: Adrenal Glands; Adrenalectomy; Aldosterone; Antihypertensive Agents; Bisoprolol; Eplerenone; Heart Failure; Humans; Hyperaldosteronism; Hypertension; Male; Middle Aged | 2023 |